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Abstract 
The prevalence of obesity in the U.S. is over 50%, and midlife obesity is a clinical 
risk factor for cognitive impairment and the onset of neurodegenerative diseases 
such as Alzheimer’s disease (1-3). Inflammation of the brain (neuroinflammation), 
a state associated with progressive neuronal loss, is heightened in cognitive 
decline and obesity (4-7). Consumption of high fat diets (HFD), specifically those 
high in the saturated fatty acid palmitic acid (C16:0; PA), exacerbate 
neuroinflammation, neurodegeneration, and cognitive impairment (8-16). 
The research presented within this thesis seeks to define the role of 
microglia in the context of obesity and cognition. The central hypothesis of my 
thesis is that high fat diets induce microglial activation resulting in altered 
immunometabolic response, neuroinflammation, and subsequent cognitive 
decline. While neuroinflammation normally increases with age, risk of 
neuroinflammation and cognitive impairment is exacerbated by obesogenic diets 
(14). The findings from this work will provide a deeper understanding of diet-
induced neuroinflammation, and will facilitate the development of novel 
therapeutics for cognitive disorders. This research has focused on utilizing basic 
science approaches to understand the effects of high fat diets on the central 
nervous system. Highlighted below are the major findings from my dissertation 
research. 
1) Orexin A-induced neuroprotection: Excess intake of dietary PA increases the
risk for developing obesity (17, 18). PA is known to induce neuronal cell death in 
the hypothalamus, a region of the brain important in regulating feeding behaviors 
(11, 19-21). One potential target to prevent this is orexin A, a hypothalamic 
signaling protein important in promoting obesity resistance that also has 
neuroprotective properties (22). I hypothesized that orexin A would protect against 
PA-induced hypothalamic cell death. To test this, I evaluated the response of 
hypothalamic neurons to orexin A and PA. I demonstrated that orexin A decreases 
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PA-induced programmed cell death and stabilizes expression of the pro-survival 
gene Bcl-2. I also demonstrated that orexin A protects against PA-induced damage 
to the mitochondria (measured via changes in reactive oxygen species (ROS) and 
mitochondrial respiration). These data support that orexin A protects against PA-
induced hypothalamic cell death. 
2) Orexin A signaling in PA-activated microglia: Obesity is associated with 
chronic low-grade inflammation, characterized by increased circulating pro-
inflammatory signals and immune cell activation (8, 11, 23). Microglia are highly 
responsive to changes throughout the brain, and communication between neurons 
and microglia depends in part on pro- or anti-inflammatory secreted signals 
(cytokines and chemokines). Furthermore, PA promotes microglia to release pro-
inflammatory signaling cascades (9, 24-26). My next goal was to determine how 
PA and orexin A treatment influences microglial secretion and activation states. To 
test this, I exposed microglial cells to orexin A and PA and measured changes in 
secreted signals. I demonstrated that orexin A treatment reduces PA-induced 
upregulation of pro-inflammatory markers and increases anti-inflammatory 
markers in microglia. Next, I sought to determine if the factors secreted by the 
activated microglia influenced neuronal survival. To test this, I filtered the microglial 
cell culture media to remove excess orexin A and PA while retaining the secreted 
cytokines, exposed neurons to this filtered supernatant, and determined neuronal 
cell death. I found that neurons exposed to media from orexin A-treated microglia 
have increased cell survival compared to those treated with media from PA-
activated microglia. This result demonstrated that microglia exposed to orexin 
secreted protective signals that protected neurons, whereas microglia exposed to 
PA alone secreted harmful cytokines that resulted in neuronal cell death. My 
findings are the first to demonstrate that orexin A modulates PA-activated 
microglial cells. 
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3) Loss of orexin and high fat diet increases cognitive impairment: Obesity is 
recognized as a risk factor for development of cognitive disorders such as 
Alzheimer’s disease (3). Moreover, deficiencies in orexin signaling have been 
linked to neurodegenerative diseases. My overall hypothesis was that reduced 
orexin signaling will increase diet-induced cognitive decline through a microglial-
mediated pathway. To test this, I used wild type (WT) mice or a mouse model of 
orexin loss to determine differences in a cognitive task. I found that mice lacking 
orexin showed significant impairments in cognition vs. WT mice. Next, to determine 
the effects of HFD on microglia and cognition, mice were placed on a HFD or 
remained on normal chow, and the cognitive task was retested at 2 and 4 weeks. 
I demonstrated that cognition was impaired and microglial activation was increased 
in mice lacking orexin given a HFD vs. WT mice. Collectively, my results show that 
orexin loss impairs cognition, and that HFD accelerate cognitive deficits and the 
onset of neuroinflammation in orexin-deficient mice. 
4) Fatty acid binding protein 4-uncoupling protein 2 axis in modulating 
microglia and cognition: Fatty acid binding proteins (FABP) are lipid chaperones 
regulating metabolic and inflammatory pathways in response to fatty acids (27, 
28). To further define a mechanism for diet-induced microglial activation and 
cognitive decline, I sought to determine if the FABP4-UCP2 (uncoupling protein 2) 
axis is involved in neuroinflammation. I hypothesized that inhibition of microglial 
FABP4 would upregulate UCP2 and attenuate PA-induced inflammation. To test 
this, I measured hypothalamic gene expression changes in WT mice and mice 
lacking FABP4 (AKO mice) fed a HFD. I found hypothalamic tissue from AKO mice 
exhibit increased UCP2 expression and reduced pro-inflammatory makers 
compared to WT mice. Next, I pharmacologically inhibited FABP4 in microglia and 
demonstrated increased UCP2 expression and reduced PA-induced pro-
inflammatory response and ROS production. Further, this effect is negated in 
microglia lacking UCP2, indicating the FABP4-UCP2 axis is pivotal in obesity-
 vii 
induced neuroinflammation. Finally, to determine if the FABP4-UCP2 axis was 
involved in attenuating diet-induced cognitive decline, WT and AKO mice were fed 
a HFD for 12 weeks and tested in a panel of cognitive tasks. I found that mice 
maintained on a HFD had reduced locomotor activity. Further, WT mice maintained 
on HFD had impaired memory, and AKO had attenuated HFD-induced memory 
impairment. Collectively, these results indicate that the FABP4-UCP2 axis is a link 
between HFD, neuroinflammation, and cognitive impairment. 
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Chapter 1 
Obesity and Brain Health 
Obesity and Public Health: 
The prevalence of obesity within the US is currently greater than 50%, with an 
estimated economic impact of over $147 billion per year in associated health care 
costs (1, 2). As obesity rates rise, so do indirect costs associated with obesity, 
including reduced years of disability-free life, increased mortality prior to 
retirement, early retirement, disability, and decreased productivity at work (29). 
Additionally, obese employees are more likely to take sick leave and obese men 
(body mass index; BMI > 40 kg/m2) are reported to have one month of lost 
productivity and cost employers $3,792 annually compared to their lean 
counterparts (29). The risk for developing comorbidities associated with obesity 
(type 2 diabetes, cardiovascular disease, cancer, and cognitive disorders), poor 
quality of life, and increased cost of health care provide reasons why it is essential 
to fully understand the underlying mechanisms driving development of obesity (3, 
30, 31). Both genetic and environmental factors contribute to the predisposition for 
obesity. Rodent and human genome-wide association studies have identified loci 
contributing to obesity and its associated comorbidities, including neuronal 
regulators of energy balance (32-34). Environmental factors including caloric 
intake, dietary composition, physical activity, and non-exercise related energy 
expenditure also contribute to the development of obesity (17, 18). Furthermore, 
once obesity is established, weight loss and maintenance is more difficult than 
would be predicted for a lean body weight that has never been obese (35, 36). 
Identifying therapeutic targets to treat and prevent obesity would be beneficial for 
maintaining quality of life and overall health of individuals, and would also have a 
positive economic impact through reduction in obesity rate and associated costs. 
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Obesity and Neuroinflammation: 
Midlife obesity is a clinical risk factor for cognitive impairment and the onset of 
neurodegenerative diseases such as Alzheimer’s disease (AD) (3). BMI is 
negatively correlated with cognitive performance and brain morphology (37, 38). A 
common link between obesity and poor brain health is chronic inflammation. 
Obesity is characterized by chronic low-level inflammation, paralleling the 
prevalence of metabolic disorders such as type-2 diabetes (8, 11, 23). Prolonged 
overnutrition and excess intake of saturated fatty acids (SFA) increases the 
amount of fatty acids in the brain and induces neuroinflammation (8-11, 39). 
Neuroinflammation is a characteristic of many neurodegenerative diseases and 
metabolic related disorders (4-7). The dietary SFA palmitic acid (PA) increases 
activation of a neurotoxic phenotype in microglia (brain immune cells), resulting in 
release of pro-inflammatory cytokines and factors that may contribute to cognitive 
decline (11, 25, 26). PA promotes the switch to a neurotoxic phenotype, triggering 
release of pro-inflammatory cytokines such as TNF-α (tumor necrosis factor-alpha) 
(9, 11), and activation of the TLR-4/NFκB pathway (toll like receptor 4/ nuclear 
factor kappa-light-chain-enhancer of activated B cells), the central regulatory 
pathway of inflammation (26). The transcriptional regulator NFκB is constitutively 
inhibited by IκB (inhibitor of NFκB). Upon stimulation of TLR-4 receptor, IκB is 
marked for degradation, allowing NFκB to initiate transcription of TNF-α. Chronic 
activation of microglia to a pro-inflammatory state can lead to reduced 
hippocampal cognitive function and neurogenesis (40-42). While 
neuroinflammation and cognitive impairment are correlated, few studies clearly 
define a mechanism that explains describes the relationship between diet-induced 
obesity, cognitive impairment, and the onset of neuroinflammation. Despite 
demonstration that SFA induces activation of microglia to a neurotoxic phenotype, 
the underlying mechanisms driving microglial activation and response to dietary 
metabolites remains undefined. 
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History of Microglia: 
Through the 20th century, the central nervous system was thought to be composed 
of two cell types, nerve cells and neuroglia, which were differentiated by their 
function. Rudolf Virchow introduced the term neuroglia (translated from the term 
nevernkitt meaning nerve-glue) to refer to non-neuronal cell types that were 
thought to be a matrix embedded with nuclei (43). Work by Santiago Ramón y 
Cajal and Pio del Río-Hortega would further redefine the term neuroglia, to the 
“third element of the nervous system”, a distinct subtype of non-neuronal cells (43). 
Upon further investigation, del Río-Hortega identified microglia, cells that were 
non-neuronal and non-astrocytic, distinct from oligodendrocytes, and had 
phagocytic and migratory capacity (43). Del Río-Hortega’s seminal work indicated 
that microglia initially arise from mesodermal cells of the pia mater as well as blood 
mononuclear cells based on their parallel behavior and morphology to monocytes 
(43). This theory was disputed for many decades until recent work confirmed del 
Río-Hortega’s theories that microglia are derived from yolk-sac macrophages early 
in development (43, 44). As early as murine embryonic day 16 (E16), macrophage-
like cells develop “hot-spots” in the brain parenchyma, where they eventually 
differentiate and become ramified microglia (45). In humans, similar events occur 
as microglial influx into the brain is detected around 22 weeks, and well-
differentiated microglial populations can be identified at 35 weeks (46). During 
development, microglial population expands rapidly, and contributes to 
neurodevelopment via secretion of neurotransmitters, cytokines, and chemokines 
(47, 48). 
Microglia constitute 5-20% of the cell population in the CNS, and are widely 
distributed throughout the brain and spinal cord (49). Until recently, microglia were 
thought to be passive, resting cells (50). Current evidence shows that microglia 
are in fact highly dynamic cells that mediate immune response, maintain synaptic 
terminals, remove debris, and secrete factors for neuronal survival (51). Microglial 
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activation can in turn activate astrocytes (CNS support cells involved in injury 
repair, synaptic transmission, and brain metabolism) to neurotoxic states that 
further increase CNS injury and promote neurodegeneration (52). Both 
macrophages and microglia share similar functions, including phagocytosis 
activity, production of ROS (reactive oxygen species), chemokines, and cytokines 
(53). Seminal classifications of microglial phenotypes were based on the 
macrophage polarization concept that “resting” microglia should be characterized 
into dichotomous phenotypes upon activation, either “M1-like” classical/neurotoxic 
and “M2-like” alternative/neuroprotective phenotypes. The M2 phenotype has 
been further sub-classified into two phenotypes: 1) M2a repair and regeneration, 
and 2) M2b immunoregulatory (54). Microglial phenotypes have been further 
classified by cell surface receptor expression and the release of cytokines and 
chemokines (Table 1.1, below). Despite the similarities and rationale for using 
macrophages to define microglial function and activation states, recent research 
has identified distinct differences in the transcriptomes of microglia and 
macrophages, mostly of proteins that sense endogenous ligands and microbes 
(53). These differences may allow microglia to behave uniquely in the CNS 
microenvironment. 
Recent shifts in perspective have appreciated microglial populations to be 
heterogeneous and therefore have begun to diverge from an “M1-M2” description. 
With advances in “omics” technologies, we are able to profile cells using high-
throughput genomic, proteomic, and computational approaches. As a result of the 
new technologies, new considerations of microglial characteristics are being taking 
into account, including genomic and proteomic profiles, brain region differences, 
continuum of aging, and patterns of response to stressors (13, 53). It should also 
be noted that microglia are self-renewing cells, and in humans have a turnover rate 
of ~4.2 years (55). Methylation, acetylation, and phosphorylation of histones or 
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Table 1.1. Proposed microglial phenotype classifications* 
 Proposed role in inflammation 
 Inflammotoxic Pro- inflammatory 
Anti- 
inflammatory Repair Immunoregulatory 
M1 cytotoxic TNF-a 
iNOS 
IL-1β 
IL-6 
IL-12 
INF-γ 
CXCL1 (KC) 
IL-1α 
IL-2 
CCL5 (RANTES) 
CX3CR1 
   
M2a repair and regeneration   COX-2 
IL-4 
IL1-RA 
CX3CR1 
TGF-β 
YM1 
FIZZ1 
IGF-1 
Arg1 
G-CSF 
GM-CSF 
CD206 
Gal-3 
CCL2 (MCP-1) 
CCR2 
M2b immunoregulatory   IL-10 
COX-2 
SphK1/2 
SOCS3 
IL-4Rα 
  
*Table modified from Chhor et al 2013 (54). 
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DNA binding proteins are influenced by pathology of various disease states 
including obesity, neuroinflammation, and AD (56-59). Given this, epigenetic traits 
should also be considered, and could potentially pass down ramified/refractory 
traits to microglia, making them less responsive to stimuli. As more data is 
generated and classified, further delineation of microglial phenotypes and 
activation characteristics will occur. Nonetheless, neuroinflammation and 
microglial activation is understood to be both beneficial or detrimental, as factors 
released from microglia can be neuroprotective or neurotoxic (9, 24, 25, 39). 
Therefore, use of rigid nomenclature and classification systems may not be the 
best approach. The research presented in this thesis has utilized current and 
available technology to survey microglial activation and phenotypes using genomic 
and proteomic approaches. For the purposes of this proposal, we reserve the 
“classical” dichotomous breakdown terminology of “M1-like” vs. “M2-like” microglial 
states to refer to those diverse microglial phenotypes that are broadly pro- or anti-
inflammatory, respectively, for the sake of simplicity only, with the full recognition 
that these descriptive groupings do not imply uniformity of phenotype within the 
classes described. 
Microglial-Neuronal Crosstalk and Cognition: 
During the normal aging process, hippocampal neuroinflammation is known to be 
increased (4). Additionally, neuroinflammation, accompanied with progressive 
neuronal loss, is heightened in cognitive decline and obesity (4). While 
hippocampal neuroinflammation normally increases with age, risk of 
neuroinflammation and cognitive impairment is exacerbated by chronic 
consumption of diets high in SFAs such as PA (14). Microglia have recently been 
appreciated to have an important role in cognition (60). In the healthy brain, 
microglia are constantly surveying the surrounding microenvironment to promote 
structural formation and elimination of neuronal synapses (60). This process is 
especially important in the hippocampus. Neuronal circuits are constantly being 
 7 
remodeled either by establishing new synapses or through elimination of selected 
synapses (defined as synaptic plasticity). In adult brains, reduced activity at 
synapses results in elimination of these connections. The events of synaptic 
plasticity are thought to underlie cognitive functions including memory formation 
and learning (61-63). Moreover, microglial/neuronal communication has been 
identified as a key mediator in this process, through internalization of synaptic 
terminals, release of signals to recruit microglia to inactivate synapses, and release 
of neurotrophic factors (64, 65). 
Increased evidence indicates that mid-life obesity is a predictor of mild 
cognitive impairment later in life (3, 31). Although cognitive decline is part of the 
normal aging process, a negative correlation between BMI and cognitive 
performance is evident when controlling for aging (66). Neuroinflammation 
represents a key link between development of mild cognitive impairment and more 
serious neurodegenerative diseases such as AD. Identification of risk factors 
associated with mild cognitive impairment and AD, including neuroinflammation, 
are of importance to develop therapeutic treatments. As such, increased circulating 
pro-inflammatory cytokines such as TNF-α are associated with cognitive decline 
and increase the risk of progressively developing AD (67). Aged microglia have 
distinct transcriptome changes. Specifically, genes associated with the Stat3 and 
Neuregulin-1 pathway are upregulated, and those associated with oxidative 
phosphorylation are downregulated (53). Moreover, differences between young (5 
mo) and aged (24 mo) microglia have differences in gene expression when 
stimulated with the pro-inflammatory stimulus interferon-γ (53). These data 
indicate that age is associated with shifts in basal microglial phenotypes and 
response to environmental stimuli. Seminal work has begun to describe dietary 
contributions to neuroinflammation, microglial phenotypes, and increased risk of 
developing cognitive impairments such as AD. In a rodent model of obesity, 
impaired cognition and altered hippocampal synaptic plasticity is evident following 
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exposure to HFD (15). Interestingly, these effects are reversed when animals are 
returned to a low fat diet (15). In a separate study, a mouse model of AD (APP23) 
fed HFD had increased AD pathology, worsened cognitive performance, and 
increased expression of genes related to immune response compared to mice fed 
normal chow (13). Moreover, in a younger cohort of HFD-fed AD mice, increased 
cognitive impairments and markers of microglial activation were evident (68). 
These data indicate that dietary effects of cognition rely in part upon microglia, and 
chronic HFD-induced microglial activation may precipitate the onset of mild 
cognitive impairment and spur a faster transition to worse outcomes such as AD. 
To better understand how diet influences cognition, a comprehensive panel of tests 
is needed. These tests examine different aspects of memory and cognition that 
utilize various brain regions. For the purpose of this thesis, the following tests were 
performed as outlined in Table 1.2. 
Neuropeptides and microglia: 
Neurons in specific hypothalamic nuclei are integral in maintaining body 
homeostasis (69). Caloric overconsumption, HFD, and obesity perturb normal 
hypothalamic function and induce hypothalamic inflammation (5, 9, 11, 24, 25). 
Recent evidence shows that the hypothalamus also has an important role in aging 
(70). One link between diet and cognitive decline could be through increased 
neuroinflammation and disrupted hypothalamic signaling. Neuropeptides activate 
neuronal and glial cells, as well as mediate multiple behaviors including eating, 
sleep/wake, reward, metabolism, reproduction, and learning and memory (5, 71-
73). Many feeding-related peptides that primarily act in the hypothalamus also 
mediate hippocampal dependent behaviors, as their receptors are highly 
expressed throughout the hippocampus (5, 71-73). Microglia can be activated via 
neuropeptides and neurotransmitters, upon activation of a receptor. Recent 
research has focused on the role of neuropeptides and microglial response in the 
context of neuroinflammation and neurodegeneration. Here, I will review the role 
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Table 1.2. Behavior testing in models of HFD-induced cognitive decline 
Behavior test Type of memory/cognition Test overview 
Brain Region 
involved 
Barnes Maze 
(74-76) 
Spatial reference 
memory: memory 
that is based on the 
constant spatial, 
contextual, and 
factual components 
of a task 
Mice learn to escape 
from a brightly lit, 
circular open 
platform to an 
escape box located 
under one of the 20 
holes around the 
perimeter of the 
platform using spatial 
reference points 
surrounding the 
maze. 
Hippocampus 
Spontaneous 
alteration T-
Maze (77) 
Short term working 
reference memory: 
response is based 
on previous actions 
Mice are placed in 
the maze which is in 
a T-shape. Mice will 
spontaneously 
alternate between 
sides of T-arm that is 
explored. 
Hippocampus 
Prefrontal cortex 
TWAA (78) Associative 
learning: learn and 
remember a 
relationship between 
unrelated items 
(CS+UC+avoidance) 
learn to cross to the 
opposite side of a 
conditioning 
chamber to avoid a 
tone-signaled foot 
shock. 
Amygdala, 
hippocampus 
Open field General locomotor 
activity and anxiety 
Animals are put in 
large open chamber 
with bright light to 
determine general 
movement. 
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of a few key neuropeptides in modulation of microglial activity. The neuropeptides 
selected are those known to have receptors expressed on microglial cells, 
indicating a potential role in inflammation, neurodegeneration, and cognition. 
Neuropeptide Y (NPY) 
NPY is a hypothalamic neuropeptide with pleotropic effects in the brain 
including strong orexigenic effects, influence on learning and memory, and anti-
inflammatory properties (79). NPY release is stimulated under fasting conditions, 
as the NPY neurons directly sense peripheral signals including blood glucose and 
leptin. In [this animal], delivery of NPY to the third ventricle improves memory 
retention in cognitive tasks (80). Conversely, in [what other animal], inhibition of 
NPY receptor Y2 and NPY knockout impair performance in cognitive tasks (81, 
82). Microglial activation is one potential mechanism through which NPY 
influences cognitive function. Recent data support that NPY modulates microglial 
response. For example, microglia treated with NPY show attenuated LPS-induced 
iNOS and IL-1β release and alters phagocytic response (83). Suppressing 
inflammation and altering phagocytic response are important behaviors in 
maintaining memory formation and preventing cognitive impairments. 
Leptin 
Leptin is an adipocyte-derived peptide that has an integral role in regulating 
appetite and energy expenditure, mediated in part via activation of hypothalamic 
neurons (84, 85). Under physiological conditions, the brain responds to increased 
leptin signaling by suppressing food intake and increasing energy expenditure (86, 
87). Overconsumption of a high fat diet is thought to induce leptin resistance and 
contribute to obesity (86, 87). Microglial activation is known to be heightened 
following high fat feeding (9, 24). Leptin receptors (LepA and LepB) are expressed 
on microglia, and once activated, these receptors initiate a pro-inflammatory 
response (88). Leptin resistance is present in obese individuals and may contribute 
 11 
to increased neuroinflammatory response (89). Additionally, leptin levels are 
increased in the hippocampus of patients with AD while leptin receptor expression 
is suppressed, indicating a link between leptin, inflammation, and 
neurodegenerative disorders (90). 
Orexin 
The orexins (hypocretins) are hypothalamic peptides, orexin A (OXA; 
hypocretin 1) and orexin B (OXB; hypocretin 2), proteolytically derived from the 
same precursor protein, preproorexin (91, 92). Orexin A and B are ligands for the 
G-protein coupled receptors orexin receptor 1 and 2 (OX1R and OX2R 
respectively). Upon activation of the orexin receptors, rapid increased intracellular 
Ca2+ influx occurs. While OX1R has greater affinity for OXA over OXB (30- to 100-
fold higher), OX2R is nonselective (92). Orexin neurons are found only in the 
lateral hypothalamus, but project throughout the central nervous system (CNS), 
including the hippocampus (93). Although orexins are more commonly recognized 
for their role in regulation of sleep/wake, arousal, feeding, and energy expenditure 
(94, 95), orexins also mediate cognitive processes, operant tasks, and fear 
conditioning (96-100). Additionally, orexin signaling is altered in AD patients (101, 
102). We and others have demonstrated that orexin loss impairs memory, 
supporting that orexin mediates cognitive function (103, 104). 
Recent studies highlight novel functions of OXA, including neuroprotection 
and decrease of apoptosis and neuroinflammation via activation of orexin 
receptors (22, 105-108). Data indicate orexin-induced neuroprotection could rely 
on microglial modulation (25, 107). In cerebral ischemia models, pretreatment with 
OXA reduces infarct size through a microglial-mediated pathway (107). 
Additionally, chronic exposure to the potent pro-inflammatory agonist 
lipopolysaccharide (LPS) reduced orexin signaling, indicating orexin has a role in 
the inflammatory response (109). Microglia may also become more sensitive to 
orexin signaling after activation (25). LPS increases TNF-α in microglia, but also 
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increases OX1R expression, and OXA treatment prior to LPS exposure reduces 
TNF-α in microglia (107). We have also demonstrated PA increases OX1R and 
PA treatment causes microglial shift to an M1-like activation state, indicated by 
increased TNF-α, IL-6, and iNOS (25). However, when microglia are pretreated 
with OXA prior to PA exposure, the PA-induced pro-inflammatory response is 
attenuated (25). These data indicate increased sensitivity to OXA may allow 
orexin-mediated attenuation of M1-like microglial phenotype to an M2-like state. 
Microglia and ROS: 
ROS, radical or non-radical oxygen containing molecules, react with lipids, 
proteins, and nucleic acids. The generation of mitochondrial ATP is coupled with 
the production and accumulation of ROS. Because of the large amount of oxygen 
consumption and ATP utilization, the brain is highly susceptible to oxidative stress 
(110). Although modest amounts of ROS act as cell signaling molecules and are 
important in nutrient sensing, chronic and sudden increases in ROS, such as those 
observed after HFD exposure, alter cell physiology and induce pathways of cell 
death (111). Moreover, oxidative stress in the brain is associated with the onset of 
neurodegenerative diseases and aging (110). In rodent models of obesity, HFDs 
increase ROS in the hippocampus and contribute to cognitive decline (112). 
Chronic exposure to pro-inflammatory stimuli including HFDs causes microglia to 
become primed and refractory, worsening the pathogenesis in neurodegenerative 
diseases, resulting in reduced hippocampal dependent cognitive function, and 
decreased neurogenesis (42, 113). Additionally, increased ROS production is 
responsible for controlling transcription of pro-inflammatory cytokines and 
phagocytosis (114). Uncoupling protein 2 (UCP2), a non-thermogenic inner 
mitochondrial membrane, dissipates the proton gradient, uncoupling mitochondrial 
metabolism from ATP production (115, 116) UCP2 also regulates the oxidative 
stress response (117). Genetic ablation of UCP2 results in increased ROS and 
inflammatory response centrally, and exacerbates neuronal cell death (118). 
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Further, UCP2 has been demonstrated to regulate microglial polarization (117). 
Neuroinflammation and Lipid Metabolism: 
Lipids are appreciated to have more than just structural properties in cells, and can 
act as vital signaling molecules. Exploration of molecular and neuroendocrine 
mechanisms within the CNS has begun to identify interactions between genetic 
and environmental inputs that regulate lipid metabolism. In model systems, 
neuropeptides have proven to have a key role in regulating total body lipid 
metabolism, however the individual cellular components are poorly defined (119-
123). In both macrophages and microglia there is a shift in energy metabolism 
depending on the stimuli. The link between inflammation and lipid metabolism 
indicates a key unexplored role in microglia, and a key role for FABP4 (fatty acid 
binding protein 4; adipocyte protein-2; aP2). Fatty acid binding proteins (FABP) 
are lipid chaperones regulating metabolic and inflammatory pathways in response 
to fatty acids (27, 28). In mice that lack FABP4 (known as FABP4/aP2-/- or AKO 
mice), high saturated fat diet feeding results in a paradoxically obese yet anti-
inflammatory phenotype, without development of metabolic syndrome (insulin 
resistance and glucose intolerance) (24, 124, 125). Prior studies have revealed 
that the mechanistic basis for the anti-inflammatory phenotype of the AKO mouse 
is driven by the FABP4-UCP2 axis (24, 125). Without FABP4, increase in UCP2 
attenuates the production of ROS, and prevents the switch to a pro-inflammatory 
state in both peripheral macrophages and microglia (24, 125). Recently, Xu et al. 
reported that ablation of FABP4 in macrophages improves mitochondrial function 
and attenuates NFκB signaling via monounsaturated fatty acid induction of UCP2 
(125). The loss of FABP4 results in increased intracellular monounsaturated fatty 
acids, predominately C16:1, that upregulate the expression of UCP2. Therefore, 
the loss of FABP4 disrupts the switch to a toxic M1-like phenotype. 
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Metabolism and Immune Cell Polarization: 
Diet-induced shift in metabolism (metabolic remodeling) is directly coupled to 
immune effector functions and can directly impact the regulation of 
microglial/macrophage transition between M1-like and M2-like phenotypes. For 
example, activation of macrophages to an M1-like state via LPS stimulation of 
TLR4 is marked by a robust upregulation of aerobic glycolysis, impaired 
mitochondrial respiration, and subsequent disruption of the tricarboxylic acid cycle 
(TCA or citrate cycle) (126, 127). These shifts are directly coupled to the 
accumulation of TCA intermediates such as itaconate (also known as methylene-
succinic acid) and succinate, resulting an increase of lactate and a decrease in 
intracellular oxygen consumption (126, 127). Recent data suggest this pathway is 
driven by upregulation of the mitochondrial-associated enzyme immune 
responsive gene-1 (Irg1), which decarboxylates aconitate to produce itaconate. 
The accumulation of itaconate results in a series of changes in the TCA cycle that 
result in M1 polarization via inhibition of succinate dehydrogenase (SDH or 
electron transport chain complex II), and through elevated succinate that cannot 
be oxidized to fumarate and malate. This remodeling of the TCA cycle in 
macrophages provides insight into the direct link between metabolic adaptation 
and immune function. 
Although microglia are known to be capable of similar metabolic shifts, the 
parallel pathways of metabolic adaptation in microglia have remained largely 
hypothetical (128), as few studies have been conducted to investigate the details 
of microglial metabolism and polarization in response to dietary metabolites, and 
downstream consequences on neuroinflammation and cognition (24). 
Overview of Chapters: 
Current evidence indicates a direct link between obesity, neuroinflammation, and 
cognitive decline. However, the pathological mechanisms of microglial immune 
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response, obesity, and cognitive impairment are not well characterized, therefore 
limited clinical treatments for individuals are available. While some degree of 
neuroinflammation is part of normal aging, age-related inflammation is 
exacerbated by metabolic perturbations and chronic consumption of high 
saturated fat diet (3, 9, 10). The central hypothesis of my thesis is that high fat 
diets induce microglial activation resulting in altered immunometabolic response, 
neuroinflammation, and subsequent cognitive decline (Figure 1.1). I will highlight 
this in the context of the role of dietary fat intake and neuroinflammation in the 
pathologic progression of neurodegeneration and cognitive function using multiple 
models of diet induced-obesity. Herein, I present a series of investigations 
intended to research mechanisms related to the microglial contributions of 
cognitive decline. The second chapter investigates the role of OXA attenuation of 
PA-induced hypothalamic cell death. Chapter 3 investigates the role of OXA 
signaling in PA-activated microglial cells. Chapter 4 investigates the role of OXA 
in HFD-induced cognitive decline. In a divergence from the topic of OXA signaling, 
in Chapter 5 I present data showing that the FABP4-UCP2 axis in microglia 
regulates inflammation. Finally, in Chapter 6 I will discuss the role of the FABP4-
UCP2 axis in diet-induced cognitive decline. My research seeks to define the role 
of microglia in the context of obesity and cognition. The findings from my work will 
provide a deeper understanding of diet-induced neuroinflammation, and will 
facilitate the development of novel therapeutics for cognitive disorders. My doctoral 
work has focused on utilizing basic science approaches to understand the effects 
of high fat diets on the central nervous system. My work utilizes multidisciplinary 
approaches including nutrition, biochemistry, pharmacology, and neuroscience to 
better understand the impact of dietary metabolites on central nervous system 
function.
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Figure 1.1. Schematic of diet induced cognitive decline. Intake of high 
saturated fat diet induces microglial activation to a pro-inflammatory phenotype 
and contributes to subsequent cognitive decline. 
Cognitive decline
High Saturated
 Fat Diet
cytokines &
markers
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Chapter 2 
Orexin A attenuates palmitic acid-induced hypothalamic cell 
death 
Introduction: 
Diets rich in the saturated fatty acid palmitic acid (PA) promote 
hypothalamic dysregulation and contribute to obesity through disruption of appetite 
regulating signals (19, 129). Mechanisms triggered by PA exposure include 
increased oxidative stress, insulin resistance, release of pro-inflammatory 
cytokines, and apoptosis (11, 19-21). In the hypothalamus, diet-induced obesity 
also alters genes regulating the apoptotic pathway. For example, hypothalamic 
expression of anti-apoptotic protein B cell lymphoma 2 (Bcl-2) is decreased, while 
expression of the pro-apoptotic protein B cell lymphoma 2 associated X protein 
(Bax) is upregulated (20). These gene expression changes are linked to obesity 
pathogenesis. High fat diets (HFD) also contribute to the overproduction of reactive 
oxygen species (ROS) in the brain, resulting in increased oxidative stress and cell 
damage (130-132). Because production of ROS is a crucial signal resulting in cell 
death, oxidative stress and apoptosis are closely related pathways. Further, ROS 
suppresses neuronal anti-apoptotic proteins including Bcl-2 (133). 
Because dietary components such as PA can directly and negatively affect 
brain health, it is likely that protection against obesity involves neural mechanisms 
capable of ameliorating diet effects on central nervous system signaling. One 
potential candidate are the orexins (hypocretins), hypothalamic peptides important 
in maintaining energy metabolism, sleep/wake cycles, and promoting obesity 
resistance (94, 134). Orexin A (OXA) and orexin B (OXB) act through two G-protein 
coupled receptors (orexin receptors 1 and 2; OX1R and OX2R, respectively) to 
alter intracellular metabolic functions (135-137) and promote cell survival against 
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oxidative stress and ischemic events (22, 138) in part through activation of Akt 
(protein kinase B) (105). Here we focus on elucidating neuroprotective pathways 
through which orexin alters brain response to PA, a major component of 
obesogenic diets. 
Work from our lab has demonstrated that OXA attenuates caspase-3/7 
mediated apoptosis in response to H2O2, an initiator of oxidative stress (22). 
Because HFDs are known to induce oxidative stress and neuronal cell death, (20, 
139) we sought to determine whether OXA protects against PA-induced cell death 
(Figure 2.1). To test this, we evaluated the response of an immortalized murine 
hypothalamic cell line (designated mHypoA-1/2) (140) to OXA. We demonstrate 
here that OXA attenuates PA-induced apoptosis via reducing caspase-3/7 activity, 
increasing Akt activation, stabilizing expression of the pro-survival gene Bcl-2, and 
inhibiting ROS production. Finally, we show that OXA alters intracellular metabolic 
function in mHypoA-1/2 cells in real-time via increased basal respiration, maximum 
respiration, ATP production, and reserve capacity. 
Methods: 
Cell culture and reagents: 
Differentiated immortalized adult mouse hypothalamic (mHypoA-1/2, cited 
elsewhere as CLU172; CELLutions-Cedarlane, Burlington ON CAN) (140, 141) 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, 
Carlsbad CA USA) supplemented with 10% fetal bovine serum (FBS) and 1% 
antibiotic cocktail (penicillin, streptomycin and neomycin) at 37°C with 5% CO2. 
The mHypoA-1/2 cells do not express endogenous orexin (142), independently 
confirmed by our laboratory (data not shown). Orexin A peptide (ThermoFisher 
Scientific, Waltham MA USA) was suspended in phosphate buffered saline (PBS; 
Invitrogen) and diluted to a final concentration of 300 nM in DMEM. Palmitic acid 
(Sigma-Aldrich, St Louis, MO USA) was suspended in dimethyl sulfoxide (DMSO) 
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Figure 2.1. Hypothesized mechanism of orexin A induced neuroprotection
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and diluted to a final concentration 0.1 mM in DMEM. Dual orexin receptor 
antagonist (DORA; TCS 1102; Tocris Bioscience, Avonmouth GBR) was 
reconstituted in DMSO and diluted to a final concentration of 1.16 nM in DMEM 
(143). The dual orexin receptor antagonist used in this study binds similarly to both 
OX1R and OX2R rapidly with high affinity (143). 
Treatments: 
In general for treatment assays, cells underwent two steps: First, a 24 h 
pretreatment with a test substance (e.g. orexin or vehicle); and second, a 2 to 24 
h challenge with palmitic acid or vehicle, with or without the test substance used 
for 24 h pretreatment. Specifically, for cell viability assays, neurons were treated 
with DORA or DMSO vehicle for 20 minutes to block orexin receptors, subjected 
to a 24 h treatment with OXA or PBS vehicle, and finally challenged with vehicle 
(PBS+DMSO), PA, DORA, or OXA for 24 h. For the caspase-3/7, ROS, and gene 
expression experiments, cells underwent 24 h pretreatment with OXA or PBS 
vehicle, followed by 2 h challenge with PA or DMSO vehicle in the presence of 
OXA or PBS vehicle. For the mitochondrial respiration assays without PA 
challenge, cells were exposed to vehicle (PBS+DMSO), OXA (50, 150, or 300 nM) 
or DORA for 2 h. For the mitochondrial assay with PA challenge, cells were first 
pretreated with OXA (300 nM) or vehicle control (PBS) for 24 h followed by a 6 h 
challenge with vehicle (PBS+DMSO), PA, or OXA. All concentrations and time 
points were based on previous studies (22, 125, 143, 144). 
Cell viability assay: 
Cell survival was determined using a resazurin-based assay (Presto Blue, 
Invitrogen) as previously described (22). Viable cells produce a fluorescent signal 
(560EX/590EM) as determined using a spectrophotometer (SpectraMax-M5; 
Molecular Devices, Sunnyvale CA USA). Data are reported as percent relative 
fluorescence units (RFU) change vs. control. 
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Caspase Activity: 
Caspase 3/7 activity was determined as previously described (22, 144). Briefly, 
caspase-3/7 activity was determined by the addition of a luminogenic caspase 
substrate DEVD based assay (Caspase-Glo 3/7, Promega, Madison WI USA). 
Changes in relative luminance units (RLU; 650 nm) were analyzed using a 
microplate spectrometer reader (SpectraMax-M5). Data are presented as fold 
increase in caspase activity normalized to cell number. 
Reactive Oxygen Species assay: 
Intracellular ROS (superoxide and hydroxyl radical) production was determined 
using a commercially available deep red fluorescence kit following manufacturer’s 
protocol (Abcam, Cambridge GBR). Cells were pretreated with OXA (or vehicle) 
for 24 h, then challenged with PA (or vehicle) plus OXA (or vehicle) for 2 h. During 
the last hour of challenge, the cell-permeable deep red dye was added to cells and 
allowed to incubate at 37°C and 5% CO2. Intracellular superoxide and hydroxyl 
radicals oxidize the deep red dye producing a fluorescent signal (145). 
Fluorescence was measured at 650EX/675EM using a spectrophotometer 
(SpectraMax-M5). Data are presented as fold change vs. control. 
Real time RT-PCR: 
Total RNA was extracted from cultured mHypoA-1/2 cells with the aid of Trizol 
reagent (Invitrogen). A final concentration of mRNA (100 ng/μl) was determined 
using 260 and 280 nm readings on a spectrophotometer (Nanodrop ND-8000; 
ThermoFisher). Primers were designed using MacVector 12 (MacVector Inc, Cary 
NC USA) and sequences are listed in table 1. Relative expression of target genes 
was determined with SYBR Green using the 2-ΔΔCT method, normalized to GAPDH 
(146).
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Table 2.1. Real-time qPCR primer sequences 
Target and 
accession 
number 
Forward primer (5ʹ to 3ʹ) Reverse primer (5ʹ to 3ʹ) 
Bcl-2 
(NM_177410.2) CACCGCGAGGGGACGCTTTG AGGTCGCATGCTGGGGCCATA 
Bax 
(NM_007527.3) GCTGAGCGAGTGTCTCCGGC ACGCGGCCCCAGTTGAAGTT 
GAPDH 
(NM_017008) GACATCAAGAAGGTGGTGAAGCAG AAGGTGGAAGAGTGGGAGTTGC 
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Cell-based enzyme-linked immunosorbent assay (ELISA): 
Changes in Akt activation were determined using a commercially available kit 
(R&D Systems, Minneapolis, MN). Briefly, cells were pretreated with OXA (or 
vehicle) for 24 h and challenged with PA (or vehicle) and an additional dose of 
OXA (or vehicle) for 1 h. Time point was based on Sokolowska et al 2014 (105). 
Cells were fixed with 4% formaldehyde, blocked, and incubated with primary 
antibodies (anti-phospho-Akt (S473) and anti-total Akt) overnight. Unbound 
primary antibodies were washed away and secondary antibodies (HRP-
conjugated or AP-conjugated) were added. Unbound secondary antibodies were 
washed away and fluorogenic substrates were added. Fluorescence was 
measured on a spectrophotometer (540EX/600EM and 360EX/450EM). Data are 
reported as the ratio of phospho-Akt normalized to total Akt in each well. 
Mitochondrial respiration assay: 
Mitochondrial function was assessed using either the XF24 or XFe96 extracellular 
flux analyzer (Seahorse Biosciences, North Billerica MA USA). Cell number and 
inhibitor titration experiments were performed for optimal response based on 
manufacturer instructions. For dose response assay, mHypoA-1/2 cells were 
plated on V7 microplates (Seahorse Biosciences) at 2x104 cells per well in DMEM 
supplemented with 10% FBS and 1% PSN and incubated overnight at 37°C in 5% 
CO2. Cells were treated with increasing concentrations of OXA (50, 150, 300 nM) 
or vehicle for 2 h (n=4-5/treatment group). Following incubation, DMEM was 
removed and replaced with XF Assay media (Seahorse Biosciences, 
supplemented with pyruvate (1 mM), L-glutamine (2 mM), and glucose (10 mM) 
containing respective treatment groups described above (147). During the assay, 
cells were treated with compounds in the following order: oligomycin (2 μM; Sigma) 
to determine mitochondrial ATP production, an uncoupler FCCP (carbonyl 
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cyanide-4-phenylhydrazone; 1.2 μM; Sigma) to determine the maximal respiration, 
and antimycin A (4 μM; Sigma) to determine the spare capacity. 
For DORA studies, cells were seeded at a density of 1x104 cells/well on XF96 
microwell plates and incubated overnight at 37°C in 5% CO2. Cells were treated 
with either vehicle control (PBS and DMSO), OXA only (300 nM), DORA only (1.16 
nM), or DORA plus OXA for 2 h (n=10-12/treatment group). Following incubation, 
DMEM was removed and replaced with XF Assay media (supplemented with 
pyruvate, L-glutamine, and glucose) containing respective treatment groups 
described above. During the assay, cells were treated with oligomycin (1 μM; 
Seahorse Biosciences), FCCP (0.5 μM; Seahorse Biosciences), and antimycin A 
(4 μM; Seahorse Biosciences). 
For OXA and PA studies, cells were seeded at a density of 2x103 cells/well on 
XF96 microwell plates and incubated overnight at 37°C in 5% CO2. Cells were then 
pretreated with vehicle (PBS) or OXA (300 nM) for 24 h and challenged with PA 
(or vehicle) and an additional dose of OXA (or vehicle) for 6 h (n=10-12/treatment). 
Time points based were on (148). Following incubation, DMEM was removed and 
replaced with XF Assay media as described above. During the assay cells were 
exposed to compounds in the following order oligomycin (1 μM; Seahorse 
Biosciences), FCCP (0.5 μM; Seahorse Biosciences), and antimycin A (4 μM; 
Seahorse Biosciences). 
The oxygen consumption rate (OCR) was automatically calculated and recorded 
by the Seahorse XFe software, respiration rates were manually calculated and 
normalized to cell number as described by Brand and Nicholls (149). The non-
mitochondrial respiration rate was calculated as the minimum rate following 
antimycin A injection. Basal respiration was determined as the last rate 
measurement before oligomycin injection minus the non-mitochondrial respiration 
rate. ATP turnover was calculated as the last rate measurement before oligomycin 
injection minus the minimum rate measurement after oligomycin injection. 
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Maximum respiration was determined by subtracting non-mitochondrial respiration 
from maximum rate measurement following FCCP injection. The reserve capacity 
was determined by subtracting the basal respiration from the maximal respiration.  
Statistical methods: 
Statistical differences were determined using a one-way ANOVA followed by 
Tukey’s post hoc test, using GraphPad Prism 5 (GraphPad Software, San Diego 
CA USA). Letters indicate significant differences between treatment groups (e.g. 
columns with the same letters do not differ from each other, while columns with 
different letters are significantly different). 
Results: 
Figure 2.2: OXA attenuates PA induced cell death: 
To determine whether OXA inhibits PA-induced neuronal cell death, mHypoA-1/2 
cells were pretreated with or without OXA (300 nM) for 24 h, and then exposed to 
PA in the presence or absence of OXA for an additional 24 h. As expected, PA 
significantly reduced cell survival (Fig 2.2A; p<0.001 vs. vehicle control; C). 
Conversely, OXA pretreatment attenuated PA-induced cell death (Fig 2.2A; p<0.05 
vs. OXA only and OXA+PA). Further, treating the cells in the presence of DORA 
negates the effects of OXA, preventing attenuation of PA-induced cell death (Fig 
2.2A; p<0.001 vs. OXA only and OXA+PA). To determine if cell death occurred via 
apoptosis, caspase-3/7 activity was measured. Hypothalamic neurons were 
pretreated with or without OXA for 24 h, and then challenged with PA in the 
presence or absence of OXA for an additional 2 h. As predicted, PA significantly 
increased caspase-3/7 activity (Fig 2.2B; p<0.0001 vs. C). However, OXA 
attenuated PA-induced caspase-3/7 activity (Fig 2.2B; p<0.0001 vs. OXA only, 
p<0.001 vs. OXA+PA).
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Figure 2.2. Orexin A attenuates PA-induced hypothalamic cell death. A) 
mHypoA-1/2 cells were pretreated with OXA for 24 h and then incubated with PA 
in the presence or absence of OXA or DORA for an additional 24 h. PA significantly 
reduces cell viability (p<0.001 vs. vehicle control; C). OXA attenuates PA induced 
cell death (p<0.05 vs. OXA only and OXA+PA). DORA negates OXA induced cell 
survival (p<0.001 vs. OXA only and OXA plus PA). B) PA significantly increases 
caspase-3/7 activity (p<0.0001 vs. C). OXA reduces caspase 3/7 induced 
apoptosis (p<0.0001 vs. OXA only, p<0.001 vs. OXA+PA).
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Figure 2.3. Orexin A reduces reactive oxygen species in mHypoA-1/2 
cells. 
Prior data indicate OXA is protective against oxidative stress (22, 105, 150). To 
determine if OXA protects against PA-induced ROS production, mHypoA-1/2 cells 
were pretreated with OXA for 24 h, and then challenged with or without PA for an 
additional 2 h. As expected, PA significantly increased ROS production compared 
to control (Fig 2.3; p<0.05). Further, in the presence of OXA, PA-induced ROS 
production was attenuated (Fig 2.3; p<0.05 PA vs. OXA+PA). 
Figure 2.4-2.6: OXA increases Akt activation and stabilizes 
expression of anti-apoptotic gene Bcl-2 
Prior reports indicate OXA activates Akt phosphorylation (105). Likewise, we 
demonstrate OXA significantly increases Akt phosphorylation with or without PA 
exposure (Fig 2.4; p<0.05 vs. C, p<0.001 vs. PA). To determine if apoptotic gene 
expression is altered following exposure to PA and OXA, changes in the anti-
apoptotic gene Bcl-2 and pro-apoptotic gene Bax were assessed. Following 2h PA 
exposure, Bcl-2 expression was significantly reduced (Fig 2.5A; p<0.05 vs. C). 
Cells treated with OXA in the presence or absence of PA had stabilized Bcl-2 gene 
expression compared to those treated with PA only (Fig 2.5A; p<0.05 vs. OXA only 
and OXA plus PA). The ratio of Bax/Bcl-2 expression was significantly upregulated 
in mHypoA-1/2 cells treated with PA only (Fig 2.5B; p<0.05 vs. C). In contrast, cells 
treated with OXA or OXA plus PA had stabilized Bax/Bcl-2 ratios (Fig 2.5B; 
p<0.001 OXA vs. PA, p<0.05 OXA+PA vs. PA). Additionally, orexin receptors 
(OX1R and OX2R) gene expression in mHypoA-1/2 cells is unchanged following 
acute 2 h PA exposure (Fig 2.6A-B).
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Figure 2.3. Orexin A reduces reactive oxygen species in mHypoA-1/2 cells. 
mHypoA-1/2 cells were pretreated with OXA for 24 h and then incubated with PA 
in the presence or absence of OXA for an additional 2 h. ROS is significantly 
increased following 2 h PA exposure (p<0.05 vs. C). OXA treatment attenuates 
PA-induced ROS production (p<0.001 vs. OXA only, p<0.05 vs. OXA+PA).  
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Figure 2.4. Orexin A increases Akt phosphorylation. mHypo-A1/2 cells were 
pretreated with OXA for 24 h and then exposed to PA in the presence or absence 
of OXA for an additional 1 h. Phosphorylated Akt is significantly increased following 
exposure to OXA in the presence or absence of PA (p<0.05 vs. C, p<0.001 vs. 
PA).  
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Figure 2.5. OXA stabilizes expression of anti-apoptotic gene Bcl-2. mHypoA-
1/2 cells were pretreated with OXA for 24 h and then challenged with PA in the 
presence or absence of OXA for an additional 2 h. A) PA significantly reduces Bcl-
2 expression (p<0.05 vs. C). OXA stabilizes Bcl-2 expression (p<0.05 vs. OXA only 
and OXA+PA). B) The Bax/Bcl-2 ratio is significantly increased following PA 
challenge (p<0.05 vs. C). However, OXA stabilizes Bax/Bcl-2 ratio (p<0.001 vs. 
OXA only, p<0.05 vs. OXA+PA). 
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Figure 2.6. Expression of OX1R and OX2R is unchanged following acute PA 
exposure. mHypoA-1/2 cells exposed to vehicle (C) or PA (0.1 mM) for 2h. 
Changes in gene expression was determined using qRT-PCR. The following 
sequences were used OX1R (NM_198959) Forward: 
GCGATTATCTCTACCCGAAGC, Reverse: CAGGGACAGGTTGACAATG and 
OX2R (NM_198962): Forward: AATCCCACGGACTATGACGACG, Reverse: 
GAGAGCCACAACGAACACGATG. 
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Figure 2.7-2.9. OXA alters metabolic respiration. 
To determine the effects of OXA on metabolic respiration, mHypoA-1/2 cells were 
treated with increasing concentrations of OXA (50, 150, and 300 nM). We show 
that OXA increased basal respiration (p<0.05 vs. C), ATP turnover (p<0.05 50, 300 
nM OXA vs. C, p<0.001 150 nM OXA vs. C) maximum respiration (p<0.05 150, 
300 nM OXA vs. C), and reserve capacity (p<0.05 150, 300 nM OXA vs. C) in a 
dose-dependent manner (Fig. 2.7A-E). This effect is directly mediated by orexin 
receptors, as treatment with DORA attenuated OXA-increased basal respiration 
(p<0.0001 DORA, DORA+OXA vs. OXA), ATP turnover (p<0.0001 DORA, 
DORA+OXA vs. OXA), maximum respiration (p<0.0001 DORA, DORA+OXA vs. 
OXA), and reserve capacity (p<0.0001 DORA vs. OXA, p<0.001 DORA+OXA vs. 
OXA; Fig. 2.8A-E). We next sought to determine if PA alters metabolic respiration 
and if OXA treatment would negate this effect. We demonstrate PA significantly 
reduced basal respiration (p<0.0001 vs. C, OXA, OXA+PA), ATP turnover 
(p<0.0001 vs. C, OXA, p<0.001 vs. OXA+PA), maximum respiration (p<0.0001 vs. 
OXA, p<0.001 vs. C, OXA+PA), and reserve capacity (p<0.05 vs. C, OXA+PA, 
p<0.0001 vs. OXA) (Fig 2.9A-E). Importantly, OXA attenuated PA-induced 
reduction in metabolic respiration (Fig 2.9A-E). 
Discussion: 
The hypothalamus is vital in sensing changes in fuel availability and 
maintaining energy balance. High fat diets contribute to hypothalamic 
dysregulation and obesity in part via increased inflammation, oxidative stress, and 
apoptosis (9, 20, 21, 25). Therefore, identifying mechanisms to prevent HFD-
induced hypothalamic dysregulation is of major importance to treating obesity. 
Data support that OXA is a mediator of obesity resistance through increased 
spontaneous physical activity (94, 134), yet the intracellular components of how 
this occurs are unclear.
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Figure 2.7. OXA alters metabolic respiration in a dose dependent manner. 
Oxygen consumption rates (OCRs) were determined in mHypoA-1/2 cells treated 
with increasing concentrations of OXA (50, 150, 300 nM) for 2 h. OXA increases 
B) basal respiration (p<0.05 vs. C), C) ATP turnover (p<0.05 50, 300 nM OXA vs. 
C, p<0.001 150 nM OXA vs. C), D) maximum respiration (p<0.05 150, 300 nM 
OXA vs. C), and E) reserve capacity (p<0.05 150, 300 nM OXA vs. C). 
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Figure 2.8. Orexin induced metabolic respiration is directly mediated by 
orexin receptors. Oxygen consumption rates (OCRs) were determined in 
mHypoA-1/2 cells treated with OXA (300 nM) and/or DORA (1.16 nM) for 2 h. OXA 
increases B) basal respiration (p<0.0001 vs. C), C) ATP turnover (p>0.001 vs. C), 
D) maximum respiration (p<0.0001 vs. C), and E) reserve capacity (p<0.05vs. C). 
Treatment with DORA attenuates OXA-increased B) basal respiration (p<0.0001 
vs. OXA), C) ATP turnover (p<0.0001 vs. OXA), D) maximum respiration 
(p<0.0001 vs. OXA), and E) reserve capacity (p<0.0001 DORA vs. OXA, p<0.001 
OXA+DORA vs. OXA).  
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Figure 2.9. Orexin stabilizes metabolic respiration. Oxygen consumption rates 
(OCRs) were determined in mHypoA-1/2 cells pretreated with OXA (300 nM) for 
24 h and challenged with PA in the presence or absence of OXA for 6 h. PA 
significantly reduces B) basal respiration (p<0.0001 vs. C, OXA, OXA+PA), C) ATP 
turnover (p<0.0001 vs. C, OXA, p<0.001 vs. OXA+PA), D) maximum respiration 
(p<0.0001 vs. OXA, p<0.001 vs. C, OXA+PA), and E) reserve capacity (p<0.05 vs. 
C, OXA+PA, p<0.0001 vs. OXA). Treatment with OXA stabilizes PA-reduced B) 
basal respiration, C) ATP turnover, D) maximum respiration, and E) reserve 
capacity. 
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Prior reports demonstrate that OXA is neuroprotective against oxidative 
stress in hypothalamic and cortical neurons (22, 105). Likewise, we show that OXA 
prevents PA-induced apoptosis through inhibition of caspase-3/7 activity (Fig 2.2A-
B). Our data show that PA increases ROS in hypothalamic cells (Fig 2.3), and 
notably, we show that OXA attenuates PA-induced ROS production (Fig 2.3). We 
also demonstrate that OXA increases Akt phosphorylation and stabilizes both Bcl-
2 expression and the Bax/Bcl-2 ratio following PA challenge (Fig 2.5-2.7). These 
data indicate that neuroprotective mechanisms of OXA rely in part on attenuation 
of ROS signaling and caspase-dependent apoptosis. To the best of our 
knowledge, this is the first report demonstrating that OXA attenuates PA-induced 
hypothalamic cell death. Diets rich in PA exacerbate the production of ROS 
throughout the brain (130, 131, 151). Further, PA induces neuronal cell death in 
part via increased ROS production (152). Although modest amounts of ROS act 
as cell signaling molecules and are important in nutrient sensing, chronic and 
sudden increases in ROS, such as those observed after HFD exposure, alter cell 
physiology and induce pathways of cell death (111). Hypothalamic neuropeptide 
Y (NPY) and pro-melanocortin (POMC) neurons are in part regulated by ROS 
signaling to control food intake (111). Further, orexin neurons directly interact with 
POMC and NPY neurons (153), suggesting one mechanism through which OXA 
suppression of ROS could contribute to obesity resistance. 
Activation of protein kinase phosphatidylinositol 3-kinase (PI3K/Akt) is 
required for stabilization of Bcl-2 expression and suppression of apoptosis in part 
through accumulation of Akt in the mitochondria (154-156). Others have 
demonstrated OXA is neuroprotective against oxidative stress via involvement of 
the PI3K/Akt signaling pathway (105, 157). Moreover, OXA may rely on increase 
mitochondrial accumulation of Akt to inhibit the onset of apoptosis (156). Under 
oxidative stress conditions, Akt accumulation in the mitochondria is inhibited (156) 
When PI3K/Akt activity is downregulated, neurons are more susceptible to 
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oxidative stress-induced cell death (158). Likewise, increased ROS leads to 
dephosphorylation of PI3K/Akt (159), indicating ROS levels play a crucial role in 
apoptosis. Phosphorylated PI3K/Akt upregulates Bcl-2 expression; conversely, 
oxidative stress downregulates Bcl-2 expression (133, 160, 161), therefore it is 
logical that OXA not only influences Bcl-2 expression but also alters mitochondrial 
function to inhibit apoptosis (156). Although others demonstrate OXA is 
neuroprotective in cortical neurons without any pretreatment (105, 106), our prior 
work (22) and data in the current study demonstrate that pretreating hypothalamic 
neurons with OXA for 24 h prior to challenge produces the most robust 
neuroprotective response (Fig 2.10). Orexin pretreatment prior to insults such as 
PA could lead to heightened activation of neuroprotective pathways, including 
increased Akt, mitogen-activated protein kinase, and hypoxia-inducible factor 1 
alpha (HIF-1α) (94, 137, 138). 
Mitochondria play an essential role in modulating ATP production, ROS, 
and apoptosis (162). Because the brain is a highly metabolically active organ, 
maintaining mitochondrial function and integrity is critically important. Mutations in 
mitochondrial proteins, impaired mitochondrial dynamics and respiration, and 
increased ROS production are associated with neurodegenerative diseases such 
as obesity, Alzheimer’s disease, and Parkinson’s disease (163-167). Therefore, 
understanding mechanisms to prevent mitochondrial disturbances are important 
for developing therapeutics for neurodegenerative diseases. Prior data indicate 
that OXA increases ATP production, indicating that OXA alters mitochondrial 
function (137). We demonstrate for the first time that OXA increases basal 
respiration, maximum respiration, ATP turnover, and reserve capacity in a dose-
dependent manner in real time (Fig 2.7A-E). Additionally, we show OXA mediated 
changes of metabolic function are attenuated in the presence of DORA (Fig 2.8A-
E). Increased reserve capacity is linked to promoting neuronal survival in models 
of oxidative stress (168, 169). Thus, the increased reserve capacity observed after 
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Figure 2.10. OXA pretreatment is necessary to increase Akt phosphorylation 
prior to simultaneously exposing mHypoA-1/2 neurons to PA and OXA. Using 
an in-cell ELISA, changes in phosphorylated Akt normalized to total Akt was 
determined following simultaneous exposure to OXA (300 nM), PA (0.1 mM), 
and/or vehicle (PBS/DMSO) control for 1 h. As expected, OXA significantly 
increases phosphorylated Akt (p<0.05 vs. C, PA, OXA+PA). When cells are 
exposed to OXA and PA simultaneously, phosphorylated Akt is not increased 
indicating 24 h pretreatment with OXA is necessary for optimal neuroprotection. 
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OXA exposure could represent a bioenergetic advantage for neuronal survival 
during PA challenge. To the best of our knowledge, we demonstrate for the first 
time that OXA stabilizes basal respiration, maximum respiration, ATP turnover, 
and reserve capacity in the presence of PA (Fig 2.9A-E). These data indicate 
increasing mitochondrial bioenergetics as a potential mechanism through which 
OXA protects against insults such as HFDs. Maintaining hypothalamic circuitry 
would be beneficial in preventing the pathophysiology of neurodegenerative 
diseases such as obesity. Mitofusin 2, a mitochondrial membrane protein, 
participates in mitochondrial fusion and has recently been implicated in obesity 
pathogenesis. Diaz et al demonstrated rodents fed a high saturated fat diet had 
impaired hypothalamic mitochondrial function and reduction in mitofusin 2 (170). 
In addition, mitochondrial dynamics governed by mitofusin 2 are integral in 
maintaining hypothalamic neurons that dictate metabolic status (170-172). As 
such, OXA-induced neuroprotective mechanisms may rely in part on altering 
proteins involved in mitochondrial dynamics. Future studies aimed at targeting the 
effects of OXA on mitochondrial dynamics and a potential role of mitofusin 2 should 
be considered in the context of obesity and neurodegenerative diseases. 
Additionally, data suggest the neuroprotective and obesity resistant mechanisms 
triggered by OXA rely on a HIF-1α-dependent pathway (138). OXA upregulates 
HIF-1α, increasing ATP production and oxidative phosphorylation by shunting 
pyruvate into the tricarboxylic acid (TCA) cycle (22, 94, 137, 173). This HIF-1α-
triggered increase in ATP could represent a biochemical mechanism through 
which OXA-producing neurons could prompt increases in cellular activity in target 
cell populations, subsequently stimulating wakefulness and other behavioral and 
physiological processes (137, 173). 
In summary, these data support that OXA is neuroprotective against PA-
induced neuronal insult in part through a ROS/caspase-dependent mechanism. 
Although in vitro studies have limitations, this work demonstrates an important 
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mechanism in which OXA alters mitochondrial function and promotes neuronal 
survival following PA challenge. Future work will explore the effects of OXA 
signaling and the relationship of long and short-term changes in mitochondrial 
function and proteins in response to HFD. Understanding the role of OXA in 
maintaining neuronal survival will provide therapeutic targets for prevention or 
treatment of neurodegenerative diseases such as obesity. 
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Chapter 3 
Role of orexin A signaling in dietary palmitic acid-activated 
microglial cells 
Introduction 
The orexins (orexins A and B; hypocretin 1 and 2) are hypothalamic 
peptides produced in lateral hypothalamic neurons and released widely throughout 
the CNS (91, 92). Orexin A (OXA) and B (OXB) regulate homeostatic mechanisms 
of energy balance and metabolism (94) through activation of two G-protein coupled 
receptors, orexin receptors 1 and 2 (OX1R and OX2R, respectively) (92). Recent 
studies have shown that orexin plays a role in neuroprotection (94, 134), in part by 
reducing lipid peroxidation, apoptosis, and inflammation (22, 105-107). Data 
suggest that the neuroprotective effects of orexin could rely on modulation of 
microglia, the resident immune cells of the brain. 
Microglia are initiators of the neuroinflammatory response and are highly 
reactive to endogenous signaling. Microglia are highly dynamic, transitioning 
between neurotoxic pro-inflammatory (M1) and neuroprotective (M2) phenotypes. 
For example, following cerebral ischemic events, microglia are first activated to a 
neuroprotective M2 phenotype as oxygen levels decrease, and then switch to a 
pro-inflammatory M1 phenotype, inducing cell death (174). While inflammation is 
a component of a normal immune response, chronic activation to M1 pro-
inflammatory phenotypes can cause microglia to become refractory and contribute 
to subsequent neuronal dysfunction (42). 
Several lines of evidence suggest a role for orexin in modulation of 
microglia. In cerebral ischemia models, pretreatment with OXA reduces infarct size 
through a microglial-mediated pathway (107). Microglia may also become more 
sensitive to orexin signaling after activation. The potent pro-inflammatory agonist 
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lipopolysaccharide (LPS) increases tumor necrosis factor alpha (TNF-α) in 
microglia, but also increases OX1R expression, and OXA treatment prior to LPS 
exposure reduces TNF-α in microglia (107). These data indicate that increased 
microglial OX1R could enhance responsiveness to orexin, thus enhancing 
capability to counter an inflammatory insult. We are especially interested in how 
these orexin-microglia dynamics might impact brain health in the context of diet-
induced obesity. 
Dietary intake influences neuronal function, overall brain health, and 
cognition (175). High fat diet increases circulating pro-inflammatory cytokines 
released from microglial cells, resulting in hypothalamic neuroinflammation and 
neurodegeneration (8, 11). Chronic intake of saturated fatty acids (SFA) such as 
palmitic acid (PA, C16:0), activate microglia to an M1 phenotype, eliciting the 
release of pro-inflammatory cytokines (9, 26). High fat diets cause this response 
by activating nuclear translocation of microglial nuclear factor-kappa B (NFκB), 
initiating release of pro-inflammatory cytokines such as TNF-α and interleukin-6 
(IL-6) (9, 11, 26). Palmitic acid activates microglia through a toll like receptor 4 
(TLR-4)-dependent pathway, inducing the release of TNF-α and IL-6 (26). Further, 
microglia activated by SFA via TLR-4 induce neuronal cell death (26). Given the 
above findings on orexin action in microglia, orexin signaling might promote 
microglia switching to a protective M2 phenotype, protecting against palmitic acid 
induced inflammation. 
The objective of these studies was to determine if orexin reduces PA-
induced neuroinflammation by altering microglial M1/M2 phenotype dynamics. To 
test whether orexin treatment influences microglial phenotype, we evaluated the 
effect of OXA on PA-induced release of pro-inflammatory cytokines in an 
immortalized murine microglial cell line (designated BV2). We first validated that 
PA activates microglia to an M1 state via TLR-4. In our next set of experiments, 
we tested whether OXA pretreatment influenced levels of the M1 pro-inflammatory 
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markers IL-6, TNF-α; inducible nitric oxide synthase (iNOS); and the M2 anti-
inflammatory marker arginase-1 in microglia. Finally, we performed a series of 
studies to determine how conditioned media from these prior tests altered 
hypothalamic neuronal survival.  
Materials and Methods 
Cell culture and reagents: 
Immortalized murine microglial cells (BV2) and adult murine hypothalamic cells 
(mHypoA-1/2, cited elsewhere as CLU172; CELLutions Biosystems) (140, 141, 
176) were grown in Dulbecco’s modified Eagle’s medium (DMEM) plus 10% fetal
bovine serum and 1% penicillin, streptomycin, and neomycin (Invitrogen) and 
maintained at 37°C with 5% CO2. Orexin A peptide (American Peptides) was 
suspended in phosphate buffered saline (PBS, Invitrogen) and diluted to 300 nM 
in DMEM. Palmitic acid (Sigma Aldrich) was conjugated to fatty acid free bovine 
serum albumin (BSA) (177) and diluted to 0.1 mM in DMEM. Lipopolysaccharide 
(Sigma Aldrich) was reconstituted in PBS and diluted to 0.4 µg (100ng/ml) in 
DMEM. The TLR-4 inhibitor TAK-242 (EMD Millipore) was reconstituted in DMSO 
and diluted to 100 nM in DMEM. 
For microglial experiments with OXA, BV2 cells were seeded in T-25 flasks 
at 7x105 cells and grown to ~80% confluency. Concentrations of OXA and PA are 
based on Xiong et al and Wang et al (26, 107). For all assays, cells were serum 
starved for 24 h. The experiment was completed in two stages: a 1 h pre-incubation 
followed by a 4 h challenge. Pre-incubation used either vehicle (PBS) or OXA (300 
nM). For challenge, cells were exposed to vehicle (fatty acid free BSA), PA (0.1 
mM), or LPS (0.4 μg; 100 ng/ml). There were a total of 5 treatment groups: vehicle-
vehicle (control), vehicle-LPS, vehicle-PA, OXA-vehicle, and OXA-PA. After 
treatment, supernatant and cells were rapidly collected and stored at -20°C. 
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Supernatant from microglial cultures treated as described here was used as 
conditioned media for hypothalamic neuronal cultures (described below). 
For microglial experiments with TAK-242, cells were seeded in 6 well plates 
at 3.5x105 cells per well and grown to ~80% confluency. Concentrations and time 
points were based on Matsunaga et al and Takashima et al (178, 179). Cells were 
serum starved for 24 h. TAK-242 (100 nM) or vehicle was added 20 minutes prior 
to incubation with PA (0.1mM) or vehicle for 4 h. 
Real-time RT-PCR: 
Total RNA was extracted from BV2 cells with Trizol (Invitrogen) as previously 
described (22, 180). Concentrations were determined using spectrophotometric 
readings at 260 and 280 nm (Nanodrop 8000, Thermo Fisher Scientific) and 2.5 
μg RNA was used for each reaction. Primer sequences were generated using 
MacVector 15 for OX1R (NM_198959), OX2R (NM_198962), IL-6 (NM_031168), 
iNOS (NM_010927), arginase-1 (NM_007482) and GAPDH (NM_017008). 
Relative mRNA expression of target genes was determined using SYBR Green 
detection normalized to GAPDH using the Δ-ΔCT method (146). 
Enzyme-linked immunosorbent assay (ELISA): 
TNF-α level in culture media was determined using an ELISA kit (BioLegend Inc.). 
Concentrations were determined using a spectrophotometer (SpectraMax-M5; 
Molecular Probes). Data are presented as picograms of TNF-α/ml. 
Cell Viability Assay for Hypothalamic Cells: 
mHypoA-1/2 cells were seeded in a 96 well plate at 5x103 cells per well overnight. 
Amicon Filters (Millipore) were used to remove PA and OXA and concentrate 
conditioned media (supernatant from microglial cultures described above) (181). 
Concentrated conditioned media was used at a six-fold concentration and added 
to mHypoA-1/2 cells for 24 h. Time points were based on previously described 
 47 
studies (26, 182, 183). Cell survival was determined using a resazurin-based 
assay (Presto Blue, Invitrogen) producing a fluorescent signal (22). Activity was 
determined using a spectrophotometer (SpectraMax-M5) and presented as 
percent relative fluorescence units (RFU) change vs. control. 
Statistical Methods: 
Significance differences were determined by unpaired, two-tailed t-tests using 
Graph Pad Prism 5. 
Results 
Palmitic acid activates BV2 microglia via TLR-4. 
To verify that PA induces pro-inflammatory cytokine release from microglial cells 
through activation of TLR-4 receptor, BV2 microglial cells were treated with the 
TLR-4 inhibitor TAK-242 (or vehicle control; C) in the presence or absence of PA 
for 4 h. As expected, PA increased TNF-α secretion by 90 percent compared to 
control, by 320 percent vs. TAK-242 only, and by 400 percent vs. TAK-242 plus 
PA (p<0.001 vs. C, p<0.0001 vs TAK-242 and TAK-242 plus PA). Treatment with 
TAK-242 significantly reduced endogenous TNF-α production. Further, TAK-242 
attenuated PA induced TNF-α secretion. (Fig. 3.1A) 
Palmitic acid increases expression of microglial orexin 1 receptor. 
To determine if PA increases microglial OX1R expression in our model, we 
pretreated BV2 microglia for 1 h with either OXA or vehicle control. Following 
pretreatment, microglia were exposed to PA, LPS, or vehicle for 4 h. Palmitic acid 
and LPS increased expression of OX1R (Fig. 3.1B; p<0.05 vs. control and OXA 
only) by 55 and 75 percent respectively, but not OX2R (Fig. 3.1C) in microglial 
cells following 4 h exposure. 
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Figure 3.1. (A) Palmitic acid activates microglia via TLR-4. TNF-  secretion 
from microglial BV2 cells increases following 4 h PA exposure. Inhibiting TLR-4 
attenuates PA–induced TNF-  secretion. Microglia treated with TLR-4 inhibitor 
(TAK-242) have significantly reduced TNF-  secretion (p<0.001 PA vs. vehicle 
control (C), p<0.0001 PA vs. TAK-242, and TAK-242+PA, p<0.001 C vs. TAK-242 
and TAK-242+PA). (B-C) Palmitic acid increases orexin 1 receptor 
expression. Microglia exposed to PA or LPS show increased OX1R expression 
(B) but not OX2R expression (C). Pretreatment of microglia with OXA before PA 
challenge increased OX1R expression and reduced OX2R expression. Different 
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letters above bars represent statistical significance at p<0.05 OXA vs. OXA/PA. 
(D) Orexin A suppresses pro-inflammatory IL-6 expression in microglial 
cells. Pro-inflammatory marker IL-6 expression is increased in BV2 microglia 
following PA and LPS exposure. Pretreatment of microglia with OXA before PA 
challenge reduces IL-6 expression compared to microglia exposed to PA only, but 
remains increased relative to vehicle (p<0.05 C vs. OXA, p<0.001 LPS vs. OXA 
and OXA/PA, p<0.001 PA vs. OXA and OXA/PA p<0.0001 C vs. LPS, PA, and 
OXA/PA). (E) Orexin A suppresses pro-inflammatory iNOS expression. 
Palmitic acid and LPS increase microglial iNOS expression, while OXA 
pretreatment attenuates PA-induced iNOS expression (PA and LPS p<0.001 vs 
control, p<0.05 vs OXA and OXA/PA). (F) Orexin A reduces TNF-α secretion 
from BV2 microglial cells. PA and LPS treatment increase TNF-α secretion 
compared to vehicle– or OXA only–treated microglia. Pretreatment of microglia 
with OXA before PA challenge reduces TNF-α secretion compared to PA only– but 
not vehicle–treated microglia. Different letters above bars represent statistical 
significance at p<0.0001. (G) Orexin A increases M2 marker arginase-1 gene 
expression. Pretreatment with OXA prior to PA challenge increases arginase-1 
gene expression (OXA/PA p<0.001 vs. control, p <0.05 vs. PA and LPS). OXA 
alone increases arginase-1 expression in microglial cells (p <0.001 OXA vs. 
control, PA, and LPS). (H) Orexin A attenuates hypothalamic neuronal cell 
death in microglial-conditioned media. Adult hypothalamic cells have increased 
cell death following 24 h exposure to conditioned media from microglia stimulated 
with PA. Hypothalamic cells exposed to conditioned media from microglia 
pretreated with OXA before PA challenge, or vehicle-treated microglia, have 
reduced cell death compared to those exposed to media from PA-challenged 
microglia. p<0.0001 Vehicle vs. PA, p<0.001 PA vs. OXA/PA, p<0.0001 PA vs. 
OXA. (I) Hypothesized Orexin A microglial immunomodulation pathway. We 
hypothesize that OXA reduces M1 microglial activation and increase M2 microglial 
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activation to maintain neuronal survival. Saturated fatty acid challenge (PA) 
induces an M1 microglial phenotype and the release of pro-inflammatory 
cytokines, contributing to neurodegeneration. Orexin A may influence proportion 
of M1 microglia by reducing rate of activation or potentially by aiding in conversion 
between M1 and M2 states. 
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Orexin A suppresses pro-inflammatory markers and increases 
expression of anti-inflammatory M2 marker arginase-1 in 
microglial cells. 
Gene expression of the pro-inflammatory cytokine IL-6 is increased by 3.5 fold 
following PA and LPS exposure (Fig. 3.1D; p<0.0001 vs. control, p<0.001 vs. OXA 
only). Further, OXA pretreatment prior to PA challenge reduced IL-6 expression by 
50 percent compared to PA only (Fig. 3.1D; p<0.0001 vs. control, p<0.001 vs. OXA 
only). Expression of pro-inflammatory marker iNOS is also increased following PA 
and LPS exposure by 60 and 75 percent respectively (Fig. 3.1E; p<0.001 vs 
control, p<0.05 vs OXA and OXA/PA). Conversely, OXA pretreatment attenuated 
PA–induced increase of iNOS expression (Fig. 3.1E). To test whether OXA 
influences TNF-α secretion in microglia, BV2 cells were pretreated with OXA or 
vehicle and challenged with PA, LPS, or vehicle as described above. An ELISA for 
TNF-α in the supernatant showed that PA and LPS treatment increased TNF-α 
secretion by 90 percent compared to vehicle control (p<0.0001) or OXA treatment 
only (p<0.0001) (Fig. 3.1F). Microglia treated with OXA plus PA reduced TNF-α 
secretion by 20 percent compared to PA only, but not to vehicle control (Fig. 1F; 
p<0.0001 vs. control and OXA only). As shown in Fig. 3.1G, OXA increased 
arginase-1 gene expression by 250 percent (p<0.001 vs. control, p <0.05 vs. PA 
and LPS). Notably, OXA pretreatment prior to PA challenge also increased 
arginase-1 expression by 100 percent (p<0.001 vs. control, PA, and LPS). 
Orexin A attenuates hypothalamic neuronal cell death in microglial-
conditioned media. 
Exposure to conditioned media from PA–treated microglia induces neuronal cell 
death due to the release of pro-inflammatory cytokines and other inflammatory 
factors (26). We tested whether OXA treatment could affect inflammatory 
properties of conditioned media from PA-challenged microglia. Hypothalamic cells 
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exposed to conditioned media from microglia treated with OXA only or pretreated 
with OXA and challenged with PA showed increased viability compared to 
hypothalamic cells exposed to conditioned media from PA–activated microglia 
(Fig. 3.1H; p<0.0006 vs. OXA, p<0.05 vs. OXA/PA). Further, cells exposed to 
conditioned media from PA–activated microglia had increased cell death 
compared to vehicle control (Fig. 3.1H; p=0.0005). 
Discussion 
Microglia are vital to neuronal health by maintaining a favorable microenvironment 
within the CNS (64, 184). Communication between neurons, microglia, and other 
CNS cells is highly dynamic and responsive to environmental stimuli. This balance 
can be disturbed if microglial activation state tips toward a chronic inflammatory 
phenotype, as is observed in obesity (9, 185, 186). An important unanswered 
question is whether it is the high fat diet or obesity itself that directly induces 
microglial activation. High fat diets and obesity, either independently or 
synergistically, have the same consequences: microglial activation and prolonged 
circulation of pro-inflammatory cytokines (9, 185, 186). Our data confirm prior 
reports indicating PA induces microglial cytokine production through a TLR-4 
dependent pathway (Fig. 3.1A) (26). We have shown that OX1R expression is 
increased in microglia challenged with PA or LPS (Fig. 3.1B). To the best of our 
knowledge, this is the first report demonstrating that PA increases OX1R 
expression in microglia.  Our data also suggest that orexin can alter the activation 
state of microglia, reducing microglial M1 pro-inflammatory state by promoting the 
conversion to M2 phenotype, as OXA pretreatment reduced microglial M1 pro-
inflammatory response during PA challenge (Fig. 3.1D-F). Consistent with 
previous reports (107), these data support that OXA can act as an 
immunomodulatory regulator of microglia. Most importantly, we show for the first 
time both that hypothalamic cells exposed to conditioned media from OXA and 
OXA/PA treated microglia have increased cell survival compared to those exposed 
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to media from PA-activated microglia without orexin, and that OXA pretreatment 
may shift microglia to an M2 protective phenotype (Fig. 3.1G-H). Our results 
demonstrate OXA modulates microglial activation states in response to PA 
exposure by reducing pro-inflammatory cytokine release and increasing anti-
inflammatory markers. 
In microglia activated by PA, addition of OXA significantly reduced iNOS 
expression. Nobunaga et al. demonstrated that microglial derived iNOS 
contributed to a loss of orexin producing neurons and subsequent metabolic 
dysfunction in mice fed a high fat diet (187). Reduction of iNOS expression due to 
OXA modulation in our study could therefore help in maintaining a favorable 
environment for surrounding cells. Likewise, conditioned media from PA-activated 
microglia did not induce hypothalamic cell death when microglia were pretreated 
with OXA prior to PA challenge. It is plausible that increasing the pretreatment time 
with OXA prior to PA exposure could further reduce pro-inflammatory cytokine 
release.  
Our findings that PA increases OX1R expression in microglial cells are 
consistent with previous findings indicating that the pro-inflammatory stimuli LPS 
also increases OX1R expression (107). Increased microglial OX1R expression in 
response to a TLR-4 mediated pro-inflammatory stimulus could represent a 
compensatory response to reduce the release of inflammatory cytokines. Others 
have demonstrated that astrocytes, a subset of glial support cells, are responsive 
to OXA through OX1R by increasing migration following OXA exposure, further 
indicating OXA is modulatory not only through neuronal cells but also glial cells 
(188). Until recently, microglia were thought to be passive support cells, but are 
now understood to contribute to fine-tuning neural-glial circuitry through cultivating 
synapses and altering plasticity in healthy and diseased brains (50, 189). 
Additionally, microglia maintain the brain microenvironment through phagocytizing 
debris, pathogens, dead cells, and misfolded proteins. In neurological disorders, 
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microglia can be chronically activated to M1 phenotypes, resulting in an 
unfavorable environment for neuronal networks (190, 191). Here we lay the 
groundwork for understanding how OXA can modulate microglia responses to 
promote neuronal survival. Performing a more complete profile of other pro– and 
anti–inflammatory cytokines in future studies could provide insight into how priming 
microglia with OXA can provide a favorable brain microenvironment and maintain 
neuronal health. While we do not yet fully know how OXA modulates microglia, 
one mechanism may be through shifting microglia towards an M2 phenotype, or at 
least slowing rate of conversion to an M1 state. In other studies of acute 
neuroinflammatory responses, microglia activated to an M2 protective phenotype, 
including increased arginase-1 expression, showed reduction in neuronal injury 
and inflammation (54, 192-194). Promotion of M2 microglial function has been 
demonstrated to either support or enhance neural-glial cross talk via increases in 
the microglial CX3CR1 (fractalkine) receptor (195). Fractalkine receptor increase 
has not been evaluated with respect to OXA stimulation, but merits further 
research. 
In summary, these data support the hypothesis that orexin influences the 
M1/M2 activation state of microglia during challenge with SFA, reducing pro-
inflammatory cytokine release to maintain neuronal survival in the surrounding 
microenvironment (Fig. 3.1). Future work will examine the implications of orexin on 
microglial dynamics in the context of diet and obesity. In other inflammatory 
diseases, microglia have been profiled to gain a better understanding of disease 
status (41). Chronic microglial activation in response to high fat diet and 
overnutrition has yet to be fully characterized. Delineating microglial phenotypes 
in the hypothalamus in response to chronic high fat diet could be useful in 
appreciating the neuropathology and the development of obesity. Understanding 
the long and short term effects of PA-activated microglia and OXA-mediated 
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immunomodulation could lead to therapies for maintaining neuronal networks 
involved in regulating healthy metabolism. 
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Chapter 4 
High fat diet increases cognitive decline and neuroinflammation 
in a model of orexin loss 
Introduction 
Obesity is coupled with peripheral and central chronic low-grade inflammation (6, 
196). Dietary fats increase the risk of developing obesity and cognitive disorders 
such as Alzheimer’s disease (AD) (3, 31, 196). Prolonged overnutrition and excess 
intake of saturated fatty acids (SFA), specifically palmitic acid (PA) increase 
neuroinflammation and microglial activation (8-11, 39). Neuroinflammation, 
accompanied with progressive neuronal loss, is known to be heightened in 
cognitive decline and obesity (4). Moreover, neuroinflammation and microglial 
activation represent a common link between age-related neurodegenerative 
diseases and metabolic related disorders. 
Microglia (resident immune cells of the brain) play a dynamic role in 
responding to changes within the surrounding environment leading to constant 
transitioning between phenotypes (197). Microglia have recently been appreciated 
to have an important role in cognition (60). In the healthy brain, microglia are 
constantly surveying the surrounding microenvironment to promote structural 
formation and elimination of neuronal synapses, a process especially important in 
the hippocampus (60). One mechanism in which this could occur is through orexin 
signaling. Orexin A and B (OXA; hypocretin 1 and OXB; hypocretin 2 respectively) 
are ligands for the G-protein coupled receptors, orexin receptor 1 and 2 (OX1R 
and OX2R respectively). Orexin neurons project throughout the central nervous 
system (CNS), including the hippocampus, and are responsible for mediating 
cognitive processes, operant tasks, and fear conditioning (93, 96-100). 
Additionally, orexin signaling is altered in AD patients (101, 102). Moreover, we 
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and others have demonstrated that orexin loss impairs memory, supporting that 
orexin mediates cognitive function (104, 198). 
Recent studies highlight novel functions of OXA, including neuroprotection 
and decreased apoptosis and neuroinflammation via activation of orexin receptors 
(22, 105-108). Data indicate that orexin-induced neuroprotection could rely upon 
microglial modulation (25, 107). In a cerebral ischemia model, pretreatment with 
OXA reduces infarct size through a microglial-mediated pathway (107). 
Additionally, chronic exposure to the potent pro-inflammatory agonist 
lipopolysaccharide (LPS), reduced orexin signaling indicating orexin has a role in 
the inflammatory response (109). Microglia may also become more sensitive to 
orexin signaling after activation (25). LPS increases TNF-α (tumor necrosis factor-
α) in microglia, but also increases OX1R expression, and OXA treatment prior to 
LPS exposure reduces TNF-α in microglia (107). We have also demonstrated that 
PA increases OX1R, and that PA treatment causes microglia to shift toward a pro-
inflammatory state (25). However, when microglia are pretreated with OXA prior to 
PA exposure, the PA-induced pro-inflammatory response is attenuated (25). 
These data indicate increased sensitivity to OXA may allow orexin-mediated 
attenuation of the toxic microglial phenotype to a protective anti-inflammatory 
phenotype. 
Our overall hypothesis is that orexin effects on memory depend in part upon 
immunomodulatory control of microglia. To test this, we used orexin/ataxin-3 
(O/A3) mice, a rodent model that gradually loses orexin-producing neurons (~84% 
by 6 mo age) (199). The O/A3 mice were maintained on a HFD for 4 weeks. We 
then sought to determine if orexin loss alters neuroinflammation and cognition. 
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Methods: 
Animals: 
7-8-month-old male wild type (WT) and orexin ataxin-3 (O/A3) mice were obtained 
from a breeding colony at the Minneapolis VA Health Care System (VAHCS). The 
colony, maintained by Dr. Catherine Kotz, originated from founder animals 
obtained from Dr. Masashi Yanagisawa at the University of Texas-Southwestern, 
bred to wild-type C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME USA). 
Genotype was confirmed using PCR as described in (199). Mice were maintained 
in a 12:12 hour light/dark cycle in a temperature controlled room(21-22°C), and 
were group-housed until the beginning of behavioral testing. Normal chow (NC; 
Teklad 8604 Lab Chow; Harlan, Indianapolis, IN USA) or high fat diet (HFD; 
Research Diets D12452, 45% fat; New Brunswick, NJ USA) and water were 
provided ad libitum. Body weights and food intake were measured thrice weekly. 
Body composition was recorded using an EchoMRI 700 (Echo Medical Systems, 
Houston, TX USA) before HFD exposure and 14 and 28 days following HFD 
exposure, as previously described (200). The experimental protocol was approved 
by the Institutional Animal Care and Use Committee at the Minneapolis VAHCS. 
Two-Way Active Avoidance (TWAA) Task: 
Mice were placed in the automated two-way shuttle box (size, 45.7 x 20.3 x 30.5 
cm; model 75-FSFX-Fusion; AccuScan Instruments, Columbus, OH USA) and 
allowed to acclimate for 2 min. Mice were able to move freely throughout the shuttle 
box during acclimation and training trials. Mice were trained on a massed 20-trial 
shuttle box two-way active avoidance task. The procedures for the conditioned 
stimulus and unconditioned stimulus were as follows. A tone (5000 Hz; 45 dB) and 
a pulsatile light (2.5 Hz) were presented as a conditioned stimulus in the 
compartment with the animal, paired 5 s later with a 0.3 mA scrambled foot shock 
(unconditioned stimulus) delivered through the floor grid (steel rods 0.5 cm in 
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diameter, spaced 1.5 cm between centers). The “scrambled” nature of the shock 
prevents the animals from finding a “no-shock” position on the floor. To avoid 
receiving a foot shock the mouse had 5 s to move to the opposite compartment. If 
the animal did not move to the other compartment, the unconditioned stimulus was 
delivered for a maximum of 7 s, and the conditioned stimulus ended with the 
unconditioned stimulus. While receiving the unconditioned stimulus, if the animal 
moved to the other compartment, both conditioned and unconditioned stimuli 
ended immediately. The inter-trial interval was variable with a mean of 40 s. A 
computer using remote monitoring system software (Fusion software) was used to 
control experimental protocols and data collection (78, 201, 202). 
TWAA Data Analysis: 
To measure performance on the TWAA task, each trial was analyzed for 
successful shock avoidances and shock latency. Experimental data were analyzed 
using two-factor (phenotype x diet) ANOVA, followed by Holm-Sidak post-hoc 
analysis for multiple comparisons. Significance was considered to be achieved 
where p<0.05. Analyses were performed to determine, a) the differences in 
acquisition between phenotypes, and b) differences in retention between treatment 
groups. The improvement of performance between training trials (first session) and 
test trials (all sessions thereafter) were analyzed for avoidances (crossing after 
conditioned stimulus, but before shock delivery) and for escape latency (interval 
between conditioned stimulus and a response). For all experiments, mice 
underwent 20 trials for training, 24 h later they were retested for TWAA response. 
Body composition was determined and mice were randomly divided into 4 groups 
and given either HFD or remained on NC (WT+NC, n = 8; WT+HFD, n = 8; 
O/A3+NC, n = 9; O/A3+HFD n = 11). Following 14 d and 28 d of diet exposure 
mice were retested for TWAA response and body composition. These parameters 
were also compared between groups during test sessions to see if there was any 
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specific effect of treatment (NC vs. HFD) on memory retention. Statistics were 
performed using GraphPad Prism 7 (78, 202). 
Locomotor activity: 
To measure exploration and general locomotor activity, mice were placed in a 
square chamber (27.3 cm x 27.3 cm x 20.3 cm; Med-Associates). The chamber is 
divided into a grid by infrared beams. An automated system monitors beam breaks 
to determine exploratory activity. Mice were allowed to explore for 2 h. All tests 
were conducted 5 h after lights on. 
Reverse transcription polymerase chain reaction (qRT-PCR): 
Hippocampal tissue was rapidly dissected from WT and O/A3 mice. Total RNA 
was isolated with the aid of TRIzol reagent (Invitrogen). Real-time thermocycling 
was performed on ABI 7900HT Fast Real Time PCR System (Applied Biosystems) 
by two-step RT-PCR using SYBR green. Genes analyzed are indicated in Table 
4.1. Data analysis was performed using Sequence Detection System software 
from Applied Biosystems. The experimental Ct (cycle threshold) was calibrated 
against the endogenous control product GAPDH. Samples were analyzed for 
relative gene expression by the ΔΔ-Ct method (203) 
Results: 
High fat diet increases obesity in orexin/ataxin-3 mice. 
We first sought to determine the effects of HFD on food intake, body weight gain 
and body composition. WT and O/A3 mice have increased cumulative food intake 
on days 6-10 (Fig 4.1A). Body weight gain is significantly increased in O/A3-HFD 
mice compared to WT-NC beginning at day 6 and continue to be significant 
through day 28 (p<0.01). WT-HFD mice have significantly increased body weight 
compared to WT-NC at day 8 through day 28 (p<0.05). Both WT and O/A3 mice 
have increased body weight compared to O/A3-NC and WT-NC at day 10 through 
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Table 4.1. qPCR Primers (5’→3’) 
Gene Forward Primer Reverse Primer 
OX1R 
(NM_198959.2) CTCATAGCCTTGGTGGGCAA ACCGACACAGCCTGGAGATA 
OX2R 
(NM_198962.3) CACGGACTATGACGACGAGG AGAGCCACAACGAACACGAT 
CX3CR1 
(NM_009987) CCGCCAACTCCATGAACAAC GGATGAGTCTGACGGCTCTG 
Iba1 
(NM_019467.2) GGAGATTTCAAAAGCTGATGTGGA CCTCAGACGCTGGTTGTCTT 
TNF-α 
(NM_001278601) AGGCACTCCCCCAAAAGATG CCACTTGGTGGTTTGTGAGTG 
Irg1 
(NM_008392.1) TATGCCAACTACTCCCCCGA CGGGAAGCTCTTAAAGGCCA 
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Figure 4.1. High fat diet increases body weight gain and fat mass. WT and 
O/A3 mice were given HFD or NC for 28 d. Cumulative food intake was increased 
after 6, 8, and 10 d HFD exposure regardless of genotype (A, *p<0.05). Mice fed 
HFD had significantly increased body weight gain days 10-28 compared to mice 
fed NC (B, * p<0.001 vs. WT-NC, # p<0.01 vs. O/A3-NC). O/A3 mice have a higher 
percent body fat compared to WT mice (***p<0.001), following 14 and 28 d on HFD 
WT and O/A3 mice have significantly more body fat compared to WT and O/A3 
mice on NC (C, *p<0.05, ****p<0.0001).
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day 28 (Fig 4.1B). Despite no significant difference in body weight, O/A3-NC mice 
have increased body fat compared to WT-NC mice on days 1, 14, and 28 (Fig 
4.1C). HFD-fed O/A3 and WT mice have increased body fat compared to NC-fed 
WT and O/A3 mice on days 14 and 28 (Fig 4.1C). High fat diet reduces locomotor 
activity but does not impair anxiety like behavior. 
To determine if changes in body fat and weight were due in part to orexin signaling, 
we analyzed locomotor activity in mice following 4 weeks HFD or NC. We 
demonstrate that locomotor activity is lower in O/A3-NC and reduced even further 
in O/A3-HFD mice (Fig 4.2A; p<0.001). To determine if anxiety-like behavior was 
altered in response to lack of orexin signaling or HFD, the first 5 min of activity was 
analyzed. We demonstrate that anxiety-like behavior (open field test) is not 
impaired in WT or O/A3 mice (Fig 4.2B). 
High fat diet impairs cognitive function in mice lacking orexin. 
Previous studies indicate that orexin is integral in cognitive function (104, 198, 
204). We sought to determine if mice lacking orexin maintained on HFD have 
impaired cognition. We demonstrated that there was no difference in learning 
ability between WT and O/A3 mice. When tested 24 h later, cognitive impairment 
was evident as measured via reduced avoidances and increased latency in O/A3 
mice (Fig 4.3A-B, p<0.01 vs. WT-NC). Mice were then placed on HFD or 
maintained on NC. Long term memory was tested following 14 and 28 d of HFD 
exposure. We demonstrate that HFD significantly impairs long term memory in 
O/A3 mice as indicated by reduced avoidances and increased latency (Fig 4.3A-
B; *p<0.05 vs. WT-NC, WT-HFD, O/A3-NC; **p<0.01 vs. WT-NC, WT-HFD, O/A3-
NC). 
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Figure 4.2. High fat diet reduces locomotor activity but does not impair 
anxiety like behavior. WT mice move significantly more compared to O/A3 mice 
fed NC or HFD (A). Anxiety-like behavior is not different between strains, as there 
were no differences in time spent in the chamber center (B). *p<0.05 O/A3-HFD 
vs. WT #p<0.05 O/A3-NC vs. WT.  
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Figure 4.3. High fat diet impairs cognitive function in mice lacking orexin. 
There is no difference in learning ability between WT and O/A3 mice. When tested 
24 h later, cognitive impairment in OA/3 is evident as measured via reduced 
avoidances and increased latency (A-B, p<0.01 vs. WT-NC). HFD significantly 
impairs long-term memory in O/A3 mice as indicated be reduced avoidances and 
increased latency compared (A-B; *p<0.05 vs. WT-NC, WT-HFD, O/A3-NC; 
**p<0.01 vs. WT-NC, WT-HFD, O/A3-NC).
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Inflammatory genes are altered in response to HFD. 
Our previous data indicate that orexin A attenuates PA-induced microglial 
inflammation (25). We demonstrate that hippocampal orexin 1 receptor is 
upregulated in mice fed HFD but orexin 2 receptor is unchanged (Fig. 4.4A-B, 
*p<0.05, **p<0.01 vs. WT-NC). Iba1, a marker of microglial activation, is increased 
in HFD-fed mice regardless of genotype, and in O/A3-NC mice (Fig 4.4C, *p<0.05, 
**p<0.01 vs. WT-NC). Pro-inflammatory marker TNF-α is increased in O/A3 mice 
(Fig 4.4D *p<0.05 vs. WT-NC, #p<0.05. ##p<0.01 vs. WT-HFD). CX3CR1 is 
upregulated following HFD exposure (Fig 4.4E, *p<0.05, **p<0.01 vs. WT-NC). 
Irg1 expression is upregulated following HFD exposure (Fig 4.4F, *p<0.05, 
**p<0.01 vs. WT-NC). 
Discussion 
High fat diets and obesity increase neuroinflammation, neurodegeneration, 
and cognitive decline (4-7). While hippocampal neuroinflammation normally 
increases with age, risk of neuroinflammation and cognitive impairment is 
exacerbated by chronic consumption of diets high in PA (6, 7). Orexins are 
important mediators in cognitive function and metabolic function (104, 198, 204). 
Moreover, pro-inflammatory stimuli have been shown to reduce orexin signaling 
(107, 109, 205, 206). Here, we demonstrate that HFD increases body weight gain 
and fat mass despite genotype (Fig 4.1). In mice lacking orexin, increased body 
weight and fat mass is observed compared to WT mice maintained on NC (Fig 
4.1). The loss of orexin also resulted in reduced locomotor activity and this effect 
is enhanced with exposure to HFD (Fig 4.2). 
It is well accepted that orexins have a distinct role in the regulation of energy 
metabolism (73), and that loss of orexin signaling contributes to increased obesity 
in part via reduced energy expenditure and movement (199). Orexin has 
pleiotropic effects in the brain as the neurons project to regions involved in 
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Figure 4.4. Inflammatory genes are altered in response to HFD. HFD but not 
orexin loss increases orexin 1 receptor (A). Orexin 2 receptor levels are unchanged 
by diet or genotype (B). HFD and loss of orexin induces microglial activation via 
increased Iba1 (C). CX3CR1 is upregulated following HFD exposure (D). The pro-
inflammatory marker TNF-α is increased in O/A3 mice (E). Irg1 expression is 
upregulated following HFD exposure (F). *p<0.05 vs. WT-NC **p<0.01 vs WT-NC 
# p<0.05 WT-HFD. 
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cognition, executive function, and learning and memory (104, 207, 208). Orexin 
loss is the causal process in the neurodegenerative disease narcolepsy, and loss 
of orexin has been implicated in comorbidities such as sleep disturbances or 
metabolic changes noted in other neurodegenerative diseases such as 
Parkinson’s, Alzheimer’s, and Huntington’s disease (209-212). While orexin loss 
has previously been considered largely to be incidental in these latter 
neurodegenerative diseases, data suggest that orexin loss may actually contribute 
to disease progression. We and others have demonstrated that OXA exhibits 
neuroprotective effects (22, 25, 105, 108). The loss of orexin could be a 
mechanism through which the brain becomes more susceptible to neuronal insults 
and increased degree of neuroinflammation. We demonstrate that mice lacking 
orexin neurons have increased cognitive deficits, and that exposure to HFD results 
in impaired long term memory in these mice (Fig 4.3). We show that both HFD 
exposure and loss of orexin increase markers of inflammation (Fig 4.4). Moreover, 
the upregulation of neuroinflammatory expression indicates that HFD accelerates 
hippocampal-dependent memory deficits and the onset of neuroinflammation in 
O/A3 mice. Our results are consistent with prior studies demonstrating 
upregulation of immune-related genes, including CX3CR1 and Irg1, in response to 
reduced orexin signaling and pro-inflammatory stimuli (126, 213). Additionally, the 
CX3CL1-CX3CR1 system, important in modulating hippocampus-specific memory 
tasks and synaptic plasticity (195, 214), is perturbed in HFD exposure, 
neuroinflammation, aging, and AD (195, 215-217). The CX3CL1-CX3CR1 system 
could represent a target for microglial-neuronal cross talk and microglial-mediated 
inflammation. Moreover, the neuroprotective immunomodulatory effects of orexin 
occur via CX3CL1-CX3CR1 signaling. Here we show mice exposed to HFD also 
have increased OX1R expression (Fig 4.4A). This is in agreement with our 
previous data demonstrating that OX1R expression is upregulated in microglia in 
response to PA, indicating that OXA effects primarily occur via OX1R signaling 
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(25, 198). Increased OX1R expression could be a mechanism in which microglia 
enhance orexin responsivity therefore enhancing the capability to appropriately 
respond to inflammatory insults. 
Future studies will focus on the effects of orexin replacement therapy in O/A3 
mice, using exogenous orexin to directly test if orexin improves cognition through 
a neuronal-glial mechanism. Orexin is necessary for consolidation of hippocampal 
dependent memory (104). Orexin treatment has been shown to improve cognitive 
performance on a variety of tasks (98-100, 204, 218-220), potentially via changes 
in long term potentiation (LTP). Other reports have demonstrated that orexin 
delivery to the CA1 region of the hippocampus improves cognition via increased 
LTP (98, 104, 221). Microglia have recently been appreciated to have a role in LTP 
and hippocampal cognition. Additionally, HFDs alter hippocampal LTP and 
microglial response (15). It is therefore reasonable to predict that orexin effects on 
cognition depend in part on modulation of microglia. To the best of our knowledge, 
we are the first to define a pathway linking orexin to phenotypic changes in 
hippocampal microglia. The data presented here indicate a targetable pathway to 
reverse diet-induced cognitive decline and treatment for neurodegenerative 
diseases involving orexin loss. 
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Chapter 5 
Identification of a Fatty Acid Binding Protein4-UCP2 Axis 
Regulating Microglial Mediated Neuroinflammation 
Introduction 
Saturated fatty acids (SFAs) such as palmitic acid (PA) contribute to the onset of 
metabolic inflammatory diseases, including obesity, in part through hypothalamic 
dysregulation and degeneration (8-11). In the hypothalamus, dietary PA activates 
microglia (immune cells of the brain) via a nuclear factor kappa B (NFκB)-mediated 
pathway to release pro-inflammatory cytokines and contribute to damage of 
neurons responsible for regulating body weight (26, 222). 
Microglia are sensitive and highly dynamic in response to changes in the 
surrounding microenvironment. As microglia respond to the surrounding 
environment, they are activated to either a pro-inflammatory (M1) or anti-
inflammatory, protective (M2) phenotype, depending on external stimuli. For 
example, PA activates microglia via a toll like receptor (TLR)-4 and induces the 
release of pro-inflammatory cytokines and factors such as tumor necrosis factor-
alpha (TNF-α) and inducible nitric oxide synthase (iNOS) (9, 25). Conversely, 
microglia activated with the anti-inflammatory cytokine interleukin (IL)-4 polarize to 
an M2 protective state, characterized by the release of anti-inflammatory cytokines 
and factors such as arginase-1 (223). The polarization of microglial cells is a highly 
energetic process and dependent upon mitochondrial integrity and activation. 
Uncoupling protein 2 (UCP2) has been implicated in mediating energetic 
processes of microglial activation states (224). Microglia activated to an M1 
phenotype have reduced UCP2 activity and expression, resulting in increased 
production of reactive oxygen species (ROS) (117). Conversely, UCP2 activity is 
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robustly increased following activation of an M2 protective phenotype (117), 
indicating a potential target to manipulate microglial activation states. 
UCP2 activity is regulated by fatty acid binding proteins (FABP), lipid 
chaperones regulating metabolic and inflammatory pathways in response to fatty 
acids (28). Targeted deletion of the adipocyte FABP (FABP4, also known as aP2) 
is sufficient to prevent obesity induced insulin resistance, diabetes, atherosclerosis 
and asthma, (124, 225-227). Mice lacking FABP4 (also referred to as aP2 deficient 
mice) have been used to extensively characterize diabetes, atherosclerosis and 
asthma linking FABP4 signaling to important roles in metabolic homeostasis and 
immunometabolic diseases, as reviewed in (28). In peripheral murine 
macrophages, the loss of FABP4 protects against the development of 
atherosclerosis and dyslipidemia (228). The loss of FABP4 in macrophages via 
either molecular or pharmacologic means results in attenuated obesity-induced 
inflammation through a UCP2-redox based mechanism (125, 148). While the role 
of the FABP4-UCP2 axis in peripheral macrophages has been extensively 
characterized, this axis has not been explored in the brain immune cells such as 
microglia. 
We hypothesized that inhibition of FBAP4 in microglia would attenuate PA-
induced pro-inflammatory response through a UCP2 mediated mechanism (Fig 
5.1). Herein we demonstrate that mice lacking FABP4 have increased expression 
of UCP2 and reduced expression of TNF-α, iNOS, and ionized calcium-binding 
adapter molecule 1 (Iba1, a marker of microglial activation) in the hypothalamus. 
Moreover, pharmacological inhibition of FABP increases UCP2 expression and 
reduces PA-induced pro-inflammatory response and ROS production. Further, this 
effect is negated in microglia lacking UCP2, indicating the FABP4-UCP2 axis is 
pivotal in obesity-induced neuroinflammation.
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Figure 5.1. Hypothesized mechanism of FABP4-UCP2 axis in microglial 
mediated neuroinflammation 
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Materials and Methods 
Cell culture and reagents: 
Immortalized murine microglial cells (BV2) and UCP2 knockdown BV2 microglia 
(UCP2kd) were grown in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen, 
Carlsbad CA USA) supplemented with 10% fetal bovine serum and 1% penicillin, 
streptomycin, and neomycin and maintained at 37°C with 5% CO2. Pan-FABP 
inhibitor (HTS01037; Cayman Chemical) was suspended in dimethyl sulfoxide 
(DMSO; Sigma Aldrich, St. Louis MO USA) and diluted to 30 μM in DMEM. Palmitic 
acid (PA; Sigma Aldrich) was conjugated to fatty acid free bovine serum (BSA; 
Sigma Aldrich) and diluted to 0.1 mM in DMEM.  
shRNA knockdown of UCP2 in microglia: 
BV2 microglia were transduced with a short hairpin RNA (shRNA) lentivirus as 
previously described (229). Green fluorescent protein (GFP) scrambled and UCP2 
targeting sequences were obtained from Open Biosystems (Pittsburgh, PA USA). 
The following were used UCP2 (GenBank accession number NM_011671) 
targeting sequence (UCP2 knockdown; UCP2kd) 5′-CCGGTCTCCCAATGTTGC-
CCGTAATCTCGAGATTACGGGCAACATTGGGAGATTTTTG-3′; scrambled 
sequence, 5′-AACGTACGCGGAATACTTCGA-3′. UCP2 expression knockdown 
is approximately 90% (Fig 5.2). 
Real-time RT PCR: 
Whole hypothalamic tissue was dissected from fifteen week old FABP4/aP2 
knockout (also referred to as AKO) and wildtype (WT) mice maintained on 60% 
high fat diet (HFD) for 12 weeks (134, 230). Mice were obtained from our breeding 
colony and the experimental protocol was approved by the Institutional Animal 
Care and Use Committee at the University of Minnesota. Total RNA was extracted 
from microglia and hypothalamic tissue with the aid of Trizol (Invitrogen) (22, 180). 
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Figure 5.2. UCP2 expression is reduced following shRNA knockdown. UCP2 
expression is reduced ~90% following shRNA knockdown (p<0.0001 vs. BV2 
cells). 
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A final concentration of mRNA was determined spectrophotometerically 
(Nanodrop ND-8000; ThermoFisher Scientific, Waltham MA USA). Real-time 
thermal cycling were carried out in a Roche LightCycler (Roche Diagnostics 
Corporation, Indianapolis, IN USA) by one-step RT-PCR using the general method 
as previously described (25). Target gene expression (Table 5.1) was determined 
using SYBR Green detection normalized to GAPDH using the Δ-ΔCT method (146).  
Amplification products were separated via electrophoresis on 3% agarose 
gels stained with SYBR green. qRT-PCR products were purified using a 
commercially available kit (MinElute PCR Purification, Qiagen Valencia CA USA) 
and validated using Sanger di-deoxyterminator sequence method at the University 
of Minnesota Genomics Center. 
Reactive oxygen species assay: 
Intracellular ROS production was determined using Deep Red Fluorescence kit 
(Abcam, Cambridge GBR) as previously described (108). Briefly, cells were 
pretreated with HTS01037 or vehicle for 3 h and then challenged with or without 
PA for 1 h (time points based on (117)). Cells were then exposed to the ROS Deep 
Red Dye for 1 h in 5% CO2 at 37°C. Intracellular superoxide and hydroxyl radicals 
react with the deep red dye, producing a fluorescent signal which was measured 
using a spectrophotometer at 650Ex/675Em (SpectraMax-M5; Molecular Devices, 
Sunnyvale CA USA). Data are presented as relative fluorescence units. 
Statistical Analysis: 
Statistical differences were determined using a one- or two-way ANOVA followed 
by Tukey’s post-hoc test (GraphPad Prism 7).
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Table 5.1. Real-time qPCR primer sequences 
Target Forward primer (5′-3′) Reverse primer (5′-3′) 
Arginase TAACCTTGGCTTGCTTCGGAAC TCTGTCTGCTTTGCTGTGATGC 
Gapdh GACATCAAGAAGGTGGTGAAGCAG AAGGTGGAAGAATGGGAGTTGC 
Iba1 GTCCTTGAAGCGAATGCTGG CATTCTCAAGATGGCAGATC 
iNos CCTACCAAAGTGACCTGAAAGAGG TTCTGGAACATTCTGTGCTGTCCC 
Tnf-α AACACAAGATGCTGGGACAGTGAC TGGAAAGGTCTGAAGGTAGGAAGGC 
Ucp2 TCGGAGATACCAGAGCACTGTCG GCATTTCGGGCAACATTGG 
Fabp4 ATGAAATCACCGCAGACGACA CATAAACTCTTGTGGAAGTCACGCC 
Fabp7 TGGCAAGATGGTCGTGACTC CCAGTGCTTCATTAGCTGGC 
Fabp5 TCCCACCATGGCCAGTCTTA ACCGTGATGTTGTTGCCATC 
 78 
Results 
Microglial cells express FABP4 and FABP5, but not FABP7. 
To verify that microglial cells express FABP, real-time PCR products of FABP4 
(Fig 5.3A), FABP5 (Fig 5.3B), and FABP7 (Fig 5.3C) were separated via 
electrophoresis and visualized on an agarose gel. Similar to macrophages, BV2 
microglial cells express both FABP4 and FABP5, whereas in total brain lysates, 
FABP4, FABP5, and FABP7 are expressed. 
Hypothalamic pro-inflammatory response is suppressed in mice 
lacking FABP4. 
In peripheral macrophages, lack of FABP4 contributes to upregulation of UCP2 
(125). To determine if the absence of FABP4 leads to upregulated UCP2 in 
microglial cells, gene expression in hypothalamic tissue from FABP4 knockout 
(referred to as AKO) and WT mice was assessed. Similar to peripheral tissue, brain 
tissue from AKO mice have upregulated UCP2 expression (Fig 5.4A; p<0.05 vs. 
WT). In peripheral macrophages, loss of FABP4 and upregulation of UCP2 is 
correlated with decreased NFκB activity, a polarization switch from M1 to M2 and 
reduced expression of inflammatory markers. Likewise, UCP2 mediates microglial 
polarization (117). Similar to the results in peripheral macrophages, hypothalamic 
tissues from wild type and AKO mice exhibited significantly reduced expression of 
Iba1, TNF-α, and iNOS compared to WT mice (Fig 5.4B-D; p<0.05). 
Inhibition of FABP leads to increased UCP2 expression in BV2 
microglial cells. 
Prior reports demonstrate UCP2 expression is increased in macrophages treated 
with the FABP inhibitor HTS01037 (125). We tested whether the same was true in 
BV2 microglia when treated with HTS01037. As predicted, UCP2 expression was 
significantly increased following HTS01037 treatment in the presence or absence 
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Figure 5.3. Microglial cells express FABP4 and FABP5 but not FABP7. A. 
Fatty acid binding protein is expressed in both whole brain (WB) and microglial 
cells. A visualization of real-time PCR products on agarose gel electrophoresis to 
evaluate gene expression. Gene product of 174 bp was expected for FABP4. B. 
FABP5 is expressed in both WB and BV2 microglial cells. Gene product of 168 bp 
was expected for FABP5. C. FABP7 is expressed in WB but not BV2 microglial 
cells. Gene product of 131 bp was expected for FABP7. L, ladder, B, water blank.  
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Figure 5.4. Hypothalamic gene expression is altered in FABP4/aP2 knockout 
animals. UCP2 expression is upregulated in FABP4/aP2 knockout mice (A; 
p<0.05 vs. WT). Pro-inflammatory genes Iba1, iNOS and TNF-α trend to be 
suppressed in FABP4/aP2 knockout mice (B-D). Letters indicate significant 
differences between treatment groups. 
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of PA (Fig 5.5; p<0.0001 C vs. HTS, p<0.001 C vs. HTS+PA, p<0.001 PA vs. HTS, 
0.05 PA vs. HTS+PA). Furthermore, the expression of UCP2 was dependent upon 
the presence or absence of FABP4, as PA alone did not alter basal UCP2 
expression (Fig 5.5).  
UCP2 is necessary for microglial inflammatory response. 
To determine if UCP2 is necessary for mediating PA-induced inflammatory 
response, we assessed changes in gene expression of iNOS in BV2 versus 
UCP2kd microglia. Exposure to PA significantly increased iNOS expression in BV2 
and UCP2kd microglia (Fig 5.6; p<0.001 PA vs. C). Inhibition of FABP attenuated 
PA-induced iNOS expression below basal levels in control cells, but iNOS was 
significantly increased in UCP2kd cells (Fig 5.6; p<0.001 PA vs. HTS, HTS+PA). 
Further, UCP2kd microglia treated with HTS01037 no longer exhibited attenuated 
PA-induced iNOS (Fig 5.6; p<0.05 C vs. HTS+PA, p<0.001 C vs. HTS, p<0.0001 
C vs. PA, p<0.0001 PA vs. HTS, HTS+PA). To determine if UCP2 is necessary to 
mediate the anti-inflammatory microglial activation, we evaluated changes in 
arginase-1 expression in BV2 and UCP2kd microglia. Arginase-1 expression was 
significantly increased in BV2 microglia exposed to HTS01037 alone or in the 
presence of PA (Fig 5.7; p<0.0001 C vs HTS, p<0.0001 PA vs. HTS, p<0.05 PA 
vs. HTS+PA). Remarkably, arginase-1 expression was significantly reduced in 
UCP2kd microglia treated with PA alone, HTS01037 only, or HTS01037 plus PA 
(Fig 5.7; p<0.0001 C vs. HTS, PA, and HTS+PA). 
UCP2 effect of ROS production in microglia. 
Next, we analyzed changes in production of ROS in BV2 and UCP2kd microglia. 
As predicted, we found that PA increased ROS production in BV2 cells (Fig 5.8; 
p<0.0001 PA vs. C), and that PA-induced ROS production was attenuated in BV2 
cells when pretreated with the FABP inhibitor HTS01037 (Fig 5.8; p<0.001 vs. HTS 
and HTS+PA). In UCP2kd microglia, HTS01037 had no effect on ROS production, 
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Figure 5.5. FABP abundance regulates UCP2 expression in microglia. UCP2 
expression is significantly upregulated following HTS01037 treatment in the 
presence or absence of PA in BV2 microglia. (p<0.0001 C vs. HTS, p<0.001 C vs. 
HTS+PA, p<0.001 PA vs. HTS, 0.05 PA vs. HTS+PA). Letters indicate significant 
differences between treatment groups.  
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Figure 5.6. UCP2 is needed to oppose PA-induced upregulation of pro-
inflammatory marker iNOS. Pretreatment with HTS01037 attenuates PA-induced 
iNOS expression in BV2 microglia (p<0.001 PA vs. C, HTS, HTS+PA). In UCP2kd 
microglia, PA increases iNOS expression, however, HTS01037 is no longer able 
to attenuate PA-induced iNOS upregulation (p<0.05 C vs. HTS+PA, p<0.001 C vs. 
HTS, p<0.0001 C vs. PA, p<0.0001 PA vs. HTS, HTS+PA). Letters indicate 
significant differences between treatment groups.  
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Figure 5.7. UCP2 mediates anti-inflammatory marker arginase-1. Pretreatment 
with HTS01037 in the presence or absence of PA robustly increases Arginase 
expression (p<0.0001 C vs HTS, p<0.0001 PA vs. HTS, p<0.05 PA vs. HTS+PA). 
In UCP2kd cells arginase-1 is no longer upregulated following HTS01037 
treatment (p<0.0001 C vs. HTS, PA, and HTS+PA). Letters indicate significant 
differences between treatment groups.  
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Figure 5.8. UCP2 effect on ROS production in microglia. BV2 cells exposed to 
PA significantly increases ROS production (p<0.0001 PA vs. C), however 
treatment with HTS01037 attenuates PA induced ROS production (p<0.001 vs. 
HTS and HTS+PA). In UCP2kd cells, PA increases ROS in the presence or 
absence of HTS01037 (p<0.0001 PA vs. C, p<0.001 HTS+PA vs. C). Letters 
indicate significant differences between treatment groups. 
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as PA significantly increased ROS production in all treatment conditions (Fig 5.8; 
p<0.0001 PA vs. C, p<0.001 HTS+PA vs. C). 
Discussion 
Obesity is often coupled with peripheral and central chronic low-grade 
inflammation (6, 196). Prolonged overnutrition and excess intake of SFA increase 
the amount of fatty acids in the brain and induce neuroinflammation (8-11, 39). The 
onset of chronic neuroinflammation has identified as a major contributor to HFD-
induced hypothalamic dysregulation (9). In addition to influencing obesity risk, 
dietary fats, such as palmitic acid, have been linked to development of cognitive 
disorders such as Alzheimer’s disease (AD) through increase in 
neuroinflammation (3, 31, 196).  
 Microglia promote neuronal health in part via maintaining a favorable 
microenvironment throughout the central nervous system (64, 184). Microglia, 
once thought to be passive support cells, are now appreciated to maintain 
neuronal-glial circuitry though removing damaged synapses and altering plasticity 
(50, 189). As observed in obesity, microglial activation state shifts towards a 
chronic pro-inflammatory phenotype (9, 185, 186). In peripheral macrophages, 
FABP dynamics alters macrophage polarization states (28, 125). Here, we 
demonstrate microglia express FABP4 and FABP5 but not FABP7 (Fig 5.3), similar 
to macrophages. Likewise, we show that mice lacking FABP4 have attenuated 
hypothalamic HFD-induced pro-inflammatory response (Fig 5.4). These findings 
are comparable to other published reports of diet induced neuroinflammation (9, 
11). Others have demonstrated HFD induces M1 microglial activation, leading to 
impaired phagocytosis and contributing to worsening pathology of 
neurodegenerative diseases including AD (231). Although not tested in this study, 
it is likely that the microglia in the FABP4/aP2 knockout animals have increased 
phagocytic function and reduced neuronal stress. Future studies will examine the 
role of microglia and cognitive function in FABP4 knockout animals. 
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In peripheral macrophages, the loss or inhibition of FABP4 results in attenuated 
obesity-induced inflammatory response via a FABP4-UCP2 mediated axis (125, 
148). Here we demonstrate the novel FABP4-UCP2 axis in microglia mediating 
PA-induced inflammation. We show UCP2 expression is increased following 
inhibition of FABP4 (Fig 5.5). Additionally, we demonstrate that inhibition of FABP4 
upregulates the anti-inflammatory marker arginase and attenuates PA-induced 
increase in iNOS (Fig 5.6). Notably, we demonstrate that when UCP2 is knocked 
down, inhibition of FABP4 no longer suppresses PA-induced iNOS expression and 
significantly reduces arginase expression (Fig 5.7). These findings demonstrate 
that UCP2 is necessary for mediating microglial polarization. The mechanistic 
relationship between iNOS and arginase 1 exists functionally at the substrate level, 
as both enzymes utilize L-arginine (232, 233). However, arginase 1 can effectively 
outcompete iNOS to downregulate production of nitric oxide, thus suppressing 
iNOS activity (232). Interestingly, L-arginine metabolism is also known to regulate 
inflammatory function of macrophages however this is unknown in microglia. In 
macrophages, increased iNOS function is associated with the pro-inflammatory 
M1 phenotype and is thought to be a part of the metabolic adaptive component of 
immune cell polarization critical to immunity and inflammation. Although this has 
been defined in macrophages, it remains unexplored in microglia. 
While evidence indicates UCP2 has a role in neuroprotection and in the 
inflammatory response, the underlying mechanisms remain unresolved. Our data 
support that promotion of the M2 microglial activation phenotype could represent 
one such mechanism, resulting in reduced ROS production and inhibition of the 
toxic M1 phenotype. We demonstrate here that treatment with HTS01037 
attenuates PA-induced ROS production in microglia, and this effect is negated 
when UCP2, a known suppressor of ROS production, is knocked down (Fig 5.8). 
To the best of our knowledge, we are the first to describe a FABP4-UCP2 axis 
regulating ROS and inflammation in microglia. Mitochondrial ROS production is a 
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key driver in the pro-inflammatory response (234). When UCP2 deficient 
macrophages are stimulated with lipopolysaccharide (LPS), ROS production and 
pro-inflammatory cytokine release is upregulated (235, 236). In microglia, LPS 
induces the reduction of UCP2, causing mitochondrial depolarization and 
increased ROS production (117). Moreover, UCP2-silenced microglia fail to 
transition to an M2 activation state (117). Collectively these findings support that 
UCP2 is necessary for activation of the M2 protective microglial phenotype. These 
observations demonstrate UCP2 is an important regulator between the FABP-free 
fatty acids (FFA) equilibrium and inflammation, which to our knowledge has not 
been previously described. 
FABP4 is expressed in multiple tissues including heart and kidney but the 
protein itself is only detectable in adipose tissue, peripheral macrophages and 
microglia (27, 28). Besides FABP4, other FABPs are also expressed in the brain. 
FABP7 is necessary for brain development, and FABP5 (mal1) is essential in 
transporting fatty acids across the blood brain barrier (27, 237). Although knocking 
out FABP5 peripherally results in attenuated diet-induced obesity, the effects are 
not as robust as in FABP4 knockout models (28). Despite the role of other FABPs 
in the brain, peripheral evidence indicates the lack of FABP4 alters the pool of free 
fatty acids, specifically, monounsaturated fatty acids (125). Monounsaturated fatty 
acids are ligands for receptors including peroxisome proliferator-activated receptor 
gamma (PPARγ), which opposes NFκB activity. Interestingly, PPARγ antagonists 
are neuroprotective in models of neurodegenerative diseases such as AD and PD, 
through a microglial-mediated mechanism (238, 239). Although not tested in the 
present study, upregulation of PPARγ could be a potential pathway though which 
the FABP-FFA equilibrium regulates the anti-inflammatory state of microglia. In 
summary, these data support a role for FABP4-UCP2 axis as a regulator of 
microglial activation states. Understanding the role of FABP and UCP2 in 
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modulating microglial activation state may provide therapeutic targets for 
prevention or treatment of neurodegenerative diseases including obesity. 
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Chapter 6 
Role of the fatty acid binding protein 4-uncoupling protein 2 axis 
in diet induced cognitive decline 
Introduction 
Obesity is often characterized by chronic low-level inflammation, paralleling the 
prevalence of metabolic disorders such as type-2 diabetes mellitus (8, 11, 23). 
Chronic neuroinflammation may be a key factor in the linkage between obesity and 
cognitive decline (3, 9, 10). Neuroinflammation, accompanied with progressive 
neuronal loss, is heightened in cognitive decline and obesity (14, 15). 
Overconsumption of high fat diets (HFD), specifically those rich in the saturated 
fatty acid (SFA) palmitic acid (PA), exacerbate neuroinflammation, 
neurodegeneration, and cognitive impairment (8-16). Rodent studies indicate that 
this is more strongly influenced by dietary SFA content than by total calories 
consumed (8, 9). Dietary PA increases activation of a neurotoxic phenotype in 
microglia (brain immune cells), resulting in release of neurotoxic cytokines that 
may contribute to cognitive decline (11, 25, 26). For example, chronic activation of 
microglia to a pro-inflammatory state can lead to reduced hippocampal cognitive 
function and neurogenesis (40-42, 240). While neuroinflammation and cognitive 
impairment are correlated, the contribution and role of microglia in the context of 
obesity is undefined. 
The link between inflammation and lipid metabolism indicates a key role for 
FABP4 (fatty acid binding protein 4; also known as adipocyte protein-2; aP2) in 
neuroinflammatory diseases such as obesity and Alzheimer’s disease (AD). 
Importantly, molecular, genetic, or pharmacologic loss of FABP4 results in an anti-
inflammatory phenotype preventing development of metabolic syndrome or 
neuroinflammatory response even in the presence of a HFD (24, 125). Without 
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FABP4, increases in UCP2, a mitochondrial membrane protein that attenuates the 
production of reactive oxygen species (ROS), prevents the switch to a pro-
inflammatory state in both peripheral macrophages and microglia (24, 117, 125). 
We hypothesized that inhibition of FABP4 attenuates HFD-induced cognitive 
decline via reduced neuroinflammation. In vivo, we demonstrate that mice 
maintained on a HFD have reduced locomotor activity. Additionally, WT mice 
maintained on HFD have impaired long term and short term memory. Further, 
these effects are negated in mice lacking FABP4. We also demonstrate that 
pharmacological inhibiting of FABP4 in primary microglia attenuates PA-induced 
pro-inflammatory cytokine secretion. Moreover, microglial pharmacological 
inhibition of FABP4 is resistant to PA-induced mitochondrial dysfunction. 
Methods: 
Cell culture and reagents: 
Primary microglia (Sciencell, San Diego, CA) were cultured in microglial growth 
medium (Sciencell) supplemented with 10% fetal bovine serum, 1% penicillin, 
streptomycin, and neomycin, and growth supplements (Sciencell) and maintained 
at 37°C with 5% CO2. Pan-FABP inhibitor (HTS01037; Cayman Chemical) was 
suspended in dimethyl sulfoxide (DMSO; Sigma Aldrich, St. Louis MO USA) and 
diluted to 30 μM in DMEM. Palmitic acid (PA; Sigma Aldrich) was conjugated to 
fatty acid free bovine serum (BSA; Sigma Aldrich) and diluted to 0.1 mM in DMEM. 
Cells were seeded in 6 well plates treated with poly-L-lysine. Cells were pretreated 
with HTS01037 or vehicle control for 3 h and challenged with PA (or vehicle) for 
12 h (24). 
Mitochondrial respiration assay: 
Mitochondrial function was assessed using the XF24 or XFe96 extracellular flux 
analyzer (Seahorse, Agilent Technologies, Santa Clara, CA). Cell number and 
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inhibitor titration experiments were performed for optimal response based on 
manufacturer instructions. BV2 microglia were seeded at a density of 8x103 
cells/well on XF96 microwell plates and incubated overnight at 37°C in 5% CO2. 
Cells were pretreated with HTS01037 (30 μM or vehicle) for 3 h and challenged 
with PA (0.1 mM or vehicle) for 4 h. Following incubation, DMEM was replaced 
with XF Assay media (Sigma), supplemented with pyruvate (1 mM), L-glutamine 
(2 mM), and glucose (10 mM). During the assay, cells were treated with 
compounds in the following order as previously described: oligomycin (1 μM; 
Sigma), FCCP (carbonyl cyanide-4-phenylhydrazone; 0.5 μM; Sigma), and 
antimycin A (4 μM; Sigma) (108). The oxygen consumption rate (OCR) was 
automatically calculated and recorded by the Seahorse XFe software, respiration 
rates were calculated using Agilent Seahorse XF Cell Mito Stress Test Report 
Generator. 
Cytokine Analysis: 
Supernatant from stimulated primary microglia were analyzed for secreted 
cytokine protein using an automated magnetic 96-well plate format (MagPix; 
Millipore). Briefly, fluorescently labeled microbeads coupled with capture 
antibodies were bound to specific target analytes, and a fluorescent or streptavidin-
labeled detection antibody. Change in fluorescence was used to yield quantitative 
analytical results (pg/ml) in cytokine abundance (54). 
Animals: 
Fifteen-week-old male FABP4/aP2 knockout (also referred to as AKO) and 
wildtype (WT) mice were maintained on 60% high fat diet (HFD) or normal chow 
(NC) for 12 weeks (230). Behavioral testing was performed following 12 weeks of 
HFD exposure. Mice were obtained from our breeding colony and the experimental 
protocol was approved by the Institutional Animal Care and Use Committee at the 
University of Minnesota. 
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Locomotor activity: 
To determine a general assessment of locomotion, animals were removed from 
the home cage and placed individually into a novel arena (22 x 42 cm) over a 2 
hour period (between 1200 and 1600). Activity was recorded by digital video and 
analyzed using Any-Maze. Data is presented as total distance traveled over 2 
hours. 
Barnes Maze: 
The Barnes maze was used to determine changes in spatial memory as previously 
described (241). Mice were placed on a white circular maze (91.44 cm diameter) 
consisting of 20 evenly spaced holes (7.5 cm apart, 5 cm diameter) located 2 cm 
from the perimeter. A black escape box, located under one of the holes (defined 
as target hole), remained in the same place throughout the training period. Distinct 
spatial cues surrounded the maze and were kept constant throughout the entire 
experiment. Animals were placed in a dark chamber in the center of the maze for 
30 seconds prior to beginning the task. Once the chamber was lifted, mice were 
able to use spatial cues to orient themselves and locate the target hole. The 
session ended when the mouse completely entered the escape box or 3 min 
elapsed. If the mouse did not enter the hole itself, it was gently guided into the 
hole. At the end of each session, the lights were turned off, the mouse was allowed 
to stay in the escape box for 10 seconds before returning to their home cage. Mice 
were trained for a total of four training sessions per day with at least a 10 min inter-
trail interval for a total of four consecutive days. Latency to target hole and average 
distance from target hole were measured over the 4 training days. On day 5, we 
tested memory of the escape location (the probe test). The escape hole was 
removed and the mouse was allowed to explore the maze for 90 sec. During the 
probe test, latency to the target hole, time spent in quadrant containing the target 
hole, and average distance from target hole were recorded (74-76). 
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T-Maze Spontaneous Alteration: 
Spontaneous alteration using the T-maze was used to determine working and 
spatial reference memory as previously described (242, 243). Briefly, mice were 
placed in the start box after 30 s, the guillotine door was opened and mice were 
allowed free choice of either arm. Choice is made when the animal’s body has 
completely entered the choice arm. Once choice has been made, animal was 
contained within the choice arm for 15 s. The mouse was then returned to the start 
box for 5 sec and allowed to again choose either arm for 10 additional trials. Choice 
arm and alterations were recorded. Percent alteration was calculated as the 
number of alterations divided by the maximum possible alterations (# of 
alterations/20*100%). 
Statistical Analysis: 
Statistical differences were determined using a one- or two-way ANOVA followed 
by Tukey’s post-hoc test (GraphPad Prism 7). 
Results: 
High fat diet increases body weight and reduces locomotor activity. 
We demonstrate that HFD increases body weight following 12 weeks HFD 
exposure despite genotype (p<0.0001; Fig 6.1). Prior studies indicate that HFD 
reduces locomotor activity (244, 245). To determine the effects of HFD on 
locomotor activity, mice were placed in an activity chamber for 2 h to measure 
general movement. We demonstrate that mice maintained on a HFD move 
significantly less compared to those maintained on NC, independent of genotype 
(p<0.01; Fig 6.2). 
Loss of FABP4 protects against diet induced cognitive decline. 
To determine the effects of FABP4 on cognition, WT and AKO mice maintained on 
HFD or NC underwent various cognitive tasks. Learning was apparent in all groups 
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Figure 6.1. High fat diet increases body weight. Body weight is increased 
following 12 week HFD intake (p<0.0001).  
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Figure 6.2. High fat diet reduces locomotor activity. Total distance traveled 
over 2 h is significantly reduced in mice fed a HFD (p<0.011). 
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in the Barnes maze task (p<0.0001; Fig 6.3B). AKO mice maintained on a HFD 
have attenuated HFD-induced memory impairment as measured by reduced 
latency to identify target hole during probe test in the Barnes maze task (Fig 6.3C). 
We demonstrate that WT mice maintained on a HFD have impaired memory as 
measured by increased latency to identify target hole during Barnes maze probe 
test (Fig 6.4C). We also demonstrated that WT-HFD mice have reduced alterations 
in T-maze, and this response is attenuated in AKO-HFD mice (Fig 6.4B). 
Inhibition of FABP4 attenuates PA-induced pro-inflammatory 
response. 
Our previous data demonstrated that inhibition of FABP4 attenuates PA-induced 
upregulation of iNOS in an immortalized microglial cell line (24). To determine a 
more detailed overview of the onset of inflammation in primary microglia, we 
utilized a more extensive cytokine array. Upon stimulation by either LPS or PA, 
several key mediators of inflammation were upregulated (TNF-α, IL-6, IL-10, IL-
13, CXCL1 (KC), IL-1α, CCL5 (RANTES), CCL2 (MCP-2) and G-CSF), a finding 
in agreement with other studies (54, 246). More importantly, inhibition of FABP4 
attenuated a wide range of key pro-inflammatory chemokines and cytokines (Fig 
6.5 A-I). 
Inhibition of FABP4 protects against PA-induced mitochondrial 
dysfunction. 
Our previous work in macrophages indicate that lack of FABP4 protects against 
HFD-induced mitochondrial dysfunction (125). To determine if microglia had 
altered metabolic response, we analyzed real time mitochondrial response 
following exposure to HTS01037 and PA. Cellular respiration assays from BV2 
microglia mirror AKO macrophage findings, (Fig. 6.6). Specifically, β-oxidative 
respiratory function was increased in microglia lacking FABP4 function when 
treated with PA.
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Figure 6.3. Loss of FABP4 is protective against HFD-induced cognitive 
decline. A. Representation of Barnes maze apparatus. Training occurred over 4 
consecutive days where mice learned to identify the target hole containing an 
escape box. B. Performance was analyzed for latency to target hole over training 
days. Performance improved significantly in all groups over duration of training 
(p<0.0001). C. During the probe (day 5), the escape hole was removed, and 
latency to target hole was analyzed. WT mice fed HFD have increased latency to 
target hole during probe test (p<0.05 vs. WT-NC, AKO-NC, AKO-HFD).  
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Figure 6.4. Loss of FABP4 rescues HFD-induced working reference memory 
decline. A. Representation of T-maze apparatus to measure spatial working 
reference memory. Mice were placed in start arm and allowed free choice to either 
goal arm. Once body fully in arm, removable partition was closed allowing mice to 
stay in goal arm for 15 s and then placed back in start area. Mice underwent an 
additional 10 trials per day for a total of 2 days. Percent alteration was calculated 
as the number of alterations divided by the maximum number of alterations. B. WT 
mice fed HFD have reduced alterations over all trails (*p<0.05 vs. WT-NC and 
AKO-NC, **p<0.01 vs. AKO-HFD).  
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Figure 6.5. Protein expression for pro-inflammatory phenotype markers 
measured in primary murine microglia. Cells pretreated with vehicle or pan-
FABP inhibitor (30 µM HTS) and 12 h PA (0.1 mM) challenge. LPS (100 ng/ml) 
used as a positive control. Expression shown as pg/ml protein, measured via 
multiplex ELISA-based Luminex Magpix assay. Data analyzed via one way 
ANOVA and Tukey’s post-test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 
vs. Control, #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 vs. HTS and 
HTS+PA.  
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Figure 6.6. FABP4-UCP2 axis in microglial mitochondrial respiration. A. 
Oxygen consumption rate (OCR), basal respiration, ATP production, max 
respiration and non-mitochondrial respiration following 4 h PA exposure. Injections 
performed in the assay include oligomycin (ATP production), FCCP (maximum 
respiration) and antimycin A & rotenone (non-mitochondrial respiration), 
respectively. B-E. Microglia exposed to PA have significantly reduced basal 
respiration, ATP turnover, maximum respiration, and proton leak. HTS01037 
(HTS) treatment rescues PA-induced changes in mitochondrial respiration. 
****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 vs. C, ###p < 0.001, #p < 0.05 
vs. PA. 
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Discussion 
Obesity and neuroinflammation are known risk factors for developing cognitive 
disorders (4-7). HFD induces activation of M1-like microglial phenotypes, leading 
to impaired immune response and contributing to either the onset of cognitive 
impairment and/or acceleration of neurodegenerative diseases such as AD (231). 
Herein, we provide evidence that HFD impairs memory, and the microglial FABP4-
UCP2 axis is involved in attenuating diet induced memory impairments. 
Microglia are dynamic cells that maintain and promote neuronal health 
throughout the CNS (64, 184). Neuronal-glial circuitry is maintained via microglia 
through removing damaged synapses and altering plasticity (50, 189). Depletion 
of microglia and subsequent neuroinflammation attenuates cognitive decline, 
indicating an important role for microglial in cognition (247). Previous studies have 
demonstrated that HFD alters microglial response contributing to cognitive decline 
(15, 248). Additionally, it has been demonstrated that microglial mediated synaptic 
pruning and hippocampal plasticity is impaired via HFD feeding (15). However, this 
effect is reversed when diet is returned to low fat (15), strongly indicating that 
dietary intake impairs microglial function. We and others have demonstrated that 
HFD, specifically PA induce microglial activation (9, 24, 249, 250). Our prior data 
demonstrate that the FABP4-UCP2 axis is central in mediating microglial 
inflammation (24). Here, we show that the microglial FABP4-UCP2 axis in part 
mediates protection against diet induced cognitive decline (Fig 6.3-4). Despite no 
differences in learning, long term spatial memory impairment was evident in WT 
mice maintained on a HFD as measured by increased latency to find escape hole 
(Fig 6.3). AKO mice maintained on HFD are protected against HFD-induced spatial 
memory impairment (Fig 6.3). Importantly, these differences are not attributed to 
motor deficits, as similar movement was observed in AKO and WT mice 
maintained on a HFD (Fig 6.2). We also demonstrate that short term working 
reference memory is impaired in WT-HFD mice and that AKO-HFD mice are 
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protected against this deficit (Fig 6.4). These findings are consistent with other 
reports (243). In adipose tissue FABP4 protein and gene expression is increased 
during HFD feeding (28, 125). Rodent and clinical data indicate that the FABP4 is 
a significant regulator of SFA-induced inflammation (24, 28, 125). Additionally, 
clinical findings support that increased FABP4 serum levels are associated with 
insulin resistance (IR) and secretion in patients with type 2 diabetes mellitus, 
suggesting that FABP4 plays an important role in peripheral glucose homeostasis 
(also linked to the onset of AD) (251, 252). Clinically, brain IR is considered an AD 
risk factor, as patients with AD present with increased IR in brain tissue (253). In 
HFD rodent models, neuronal IR paired with impaired spatial working memory has 
been reported (243). One mechanism in brain tissue could be lipotoxicity, which 
can impair glucose homeostasis and induce inflammation, due in part to activation 
of neurotoxic M1 microglial phenotypes, which can precipitate the onset of brain 
IR (21). The microglial FABP4-UCP2 axis represents an important mediator in this 
process, and under HFD conditions this axis is perturbed, ultimately resulting in 
cognitive decline.  Future studies to determine the effects of the FABP4-UCP2 axis 
on brain IR are ongoing. While other groups have determined that FABP5 (E-
FABP) KO mice demonstrate impaired cognitive function, it appears that this is due 
in part to decreased DHA (docosahexaenoic acid) metabolism within brain tissue 
(237, 254). A cell-type specific contribution has not been positively identified, but 
brain endothelial cells (at the blood brain barrier), not microglia, are thought to be 
the most salient contributing cell type (255). 
Our prior work demonstrates that loss or inhibition of FABP4 results in 
reduced microglial pro-inflammatory expression of iNOS and TNF-α via a FABP4-
UCP2 mediated axis (24). We show microglia treated with LPS or PA induce the 
upregulation of pro-inflammatory cytokines (TNF-α, IL-6, IL-10, IL-13, CXCL1 
(KC), IL-1α, CCL5 (RANTES), CCL2 (MCP-2) and G-CSF; Fig 6.5), a finding in 
agreement with other studies (54, 246). More importantly, inhibition of FABP4 
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attenuated a wide range of key pro-inflammatory chemokines and cytokines (Fig 
6.5 A-I). These findings indicate that UCP2 is necessary for mediating microglial 
inflammatory response. Seminal research has begun to define the links between 
dietary intake, metabolism, peripheral inflammation, and neuroinflammation (13, 
24, 125-127). Diet-induced shifts in metabolism (metabolic remodeling) are directly 
coupled to immune effector functions and can directly impact the regulation of 
microglial/macrophage transition between pro- and anti-inflammatory phenotypes. 
For example, activation of macrophages to an M1-like (toxic) state via LPS 
stimulation of TLR4 is marked by a robust upregulation of aerobic glycolysis, 
impaired mitochondrial respiration, and disruption of the tricarboxylic acid cycle 
(TCA or citrate cycle) (126, 127). These shifts are directly coupled to accumulation 
of TCA intermediates such as itaconate and succinate, resulting in increased 
lactate and decreased intracellular oxygen consumption (126, 127). This pathway 
is driven by upregulation of the mitochondria-associated enzyme Irg1 (127). This 
remodeling of the TCA cycle in macrophages demonstrates the direct link between 
metabolic adaptation and immune function. Likewise, we show that inhibition of 
FABP4 protect microglia from PA-induced loss of β-oxidative mitochondrial 
respiration capacity (Fig 6.6). These results confirm other findings that pro-
inflammatory stimuli shift from primarily oxidative metabolism to a glycolytic state 
(194, 256). 
Multiple studies have demonstrated that lipid metabolism changes are 
associated with development of cognitive decline and increased risk of AD (5, 13, 
15, 250, 257). In transgenic AD mice (APP23), HFD alters the brain transcriptome, 
lipid metabolism, and lipid composition, resulting in altered brain immune response 
(13). Additionally, HFDs alter phospholipid subspecies linked to 
neuroinflammation, mitochondrial dysfunction, oxidative stress, and cognitive 
deficits (13, 258). However, these studies largely focused on whole brain tissue 
samples, and therefore do not reveal individual contributions of microglia. Recent 
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data shows that single-cell RNA sequencing (scRNA-seq) is an effective tool for 
defining microglial immunoheterogeneity in models of AD (259, 260). To identify 
microglial phenotypes during HFD-induced cognitive decline, single-cell scRNA-
seq to perform a comprehensive analysis for identification of genes regulating 
brain immune system and innate immune response pathways and regulatory 
factors within the FABP4-UCP2 axis are ongoing. Further work is necessary to 
understand the role of HFD, microglial lipid metabolism, and cognitive decline. 
Collectively, our data demonstrate that FABP4–UCP2 axis alters immune cell 
metabolism during HFD and obesity. The FABP4-UCP2 axis represents a novel 
target for the treatment of inflammation-induced neurodegeneration and cognitive 
decline. 
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Chapter 7 
Summary 
Despite extensive studies in models of obesity and aging understanding of 
neuroinflammation and cognitive decline is incomplete. The aim of my work was 
to define central regulators of microglial immune response in the context of obesity 
and cognitive decline. To pursue these studies, transdisciplinary approaches 
(nutritional biochemistry, pharmacology, and neuroscience) were applied to 
understand how dietary metabolites affect the central nervous system. 
The epidemic of chronic diseases, including dementia and neurological 
related disorders, is linked to aging (261). Neurological diseases are one of the 
leading contributors to disease burden. Individuals over the age of 60 years, and 
results in disability rather than mortality (261). The societal cost of age-related 
diseases is rapidly increasing. The financial burden of dementia related care in the 
US was $157-215 billion annually (2010) and is projected to cost $511 billion by 
2040 (262). Additionally, the economic cost of obesity is over $147 billion annually, 
and midlife obesity is a clinical risk factor for cognitive impairment and 
neurodegenerative diseases including AD (1-3). Therefore, the development for 
treatment of cognitive related disorders important. The work presented here lends 
to this public health crisis by leveraging transdisciplinary approaches (nutritional 
biochemistry, pharmacology, and neuroscience) to understand how obesity 
influences microglia and cognition.  
Overnutrition induces metabolic syndrome (obesity, insulin resistance, and 
glucose intolerance) and inflammation (8, 23, 263). Chronic neuroinflammation 
represents a key link between obesity and cognitive decline (3, 9, 10). While 
neuroinflammation and cognitive impairment are correlated, few studies clearly 
define a mechanism that explores the relationship between diet-induced obesity 
the onset of neuroinflammation in microglia. The aim of my work was to define the 
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role of microglia in the context of obesity and cognition. The central hypothesis of 
my thesis was that HFD induce microglial activation resulting in altered 
immunometabolic response, neuroinflammation, and subsequent cognitive 
decline. Here, I presented data that support PA and HFD induce 
neuroinflammation and multiple durations of HFD exposure (chronic and short 
term) in multiple rodent models (O/A3 and WT) contributes to cognitive decline. 
Microglia are highly dynamic in that they mediate immune responses, maintain 
synaptic terminals, remove debris, and secrete factors for neuronal survival. 
Previous reports indicate that exposure to chronic overnutrition and HFD, synaptic 
pruning and maintained of synaptic terminals is impaired (15). In models of AD, 
microglial synaptic pruning is heightened and correlated to cognitive deficit (264). 
Therefore, maintaining microglial homeostasis especially in the hippocampus, 
where neuronal-glial crosstalk is highly dynamic and responsive to environmental 
stimuli such as HFD is important to preserving cognitive function  (15). 
I also demonstrate the loss of FABP4 attenuates diet induced 
neuroinflammation and cognitive decline. Importantly, molecular, genetic, or 
pharmacologic loss of FABP4 results in an anti-inflammatory phenotype and an 
M1-like to M2-like phenotypic shift in microglia, preventing development of 
metabolic syndrome or neuroinflammatory response even in the presence of a high 
saturated fat diet (24). While hippocampal neuroinflammation is part of normal 
aging, risk of cognitive impairment increases with chronic consumption of diets 
high in saturated fat and with metabolic perturbations such as insulin resistance 
(IR), especially during mid-life (3, 12, 14, 243, 265). HFD induces activation of M1-
like microglial phenotypes, leading to impaired immune response and contributing 
to either the onset of cognitive impairment and/or acceleration of 
neurodegenerative diseases such as AD (231). Altered brain glucose is inherent 
to AD pathology and may present prior to symptoms of the disease (266). 
Additionally, increased concentration of brain glucose is associated with greater 
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severity of AD pathology (266). In human brains, AD pathology and increased brain 
glucose is also associated with increase markers of glycolysis (266).  
Microglia activated to an M1-like state also have increased glycolytic 
markers (267). In macrophages lacking FABP4, markers of glycolysis are reduced 
(125). I demonstrate that the loss of FABP4 is protective against PA-induced 
disruption of mitochondrial biogenesis. The FABP4-UCP2 axis in microglia in the 
context of metabolic reprogramming, HFD and AD have been relatively 
unexplored, however it would be reasonable to predict that loss of FABP4 in 
microglia would reduce markers of glycolysis and could be a mechanism in which 
the loss of FABP4 is protective against HFD-induced cognitive decline. Previous 
work has demonstrated that HFD induces neuronal insulin resistance paired with 
impaired working memory in rodents (243). One mechanism in brain tissue could 
be lipotoxicity, which can impair glucose homeostasis and induce inflammation, 
due in part to activation of pro-inflammatory (M1-like) microglial phenotypes, which 
can precipitate the onset of brain IR (21). Interestingly, both microglia and 
macrophages exposed to pro-inflammatory stimuli have altered intracellular lipid 
content (increased SFA and reduced MUFA). This has been demonstrated to 
directly alter immune cell polarization. In macrophages lacking FABP4, MUFA 
concentration is increased and contributes to polarization to a protective 
phenotype in part via increased oxidative phosphorylation and reduced glycolysis 
(125). In the healthy brain, microglia are constantly surveying the surrounding 
microenvironment to promote structural formation and elimination of neuronal 
synapses (15). This process is especially important in the hippocampus, where 
neuronal-glial crosstalk is highly dynamic and responsive to environmental stimuli 
such as HFD (15). Future work should address the impact of the FABP4-UCP2 
axis in regulating microglial polarization and metabolic reprogramming in response 
to HFD and cognitive decline. 
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Changes in lipid metabolism have been associated with cognitive decline 
and Alzheimer’s disease (5, 13, 15, 250, 257). Collectively rodent and clinical data 
support obesity alters the brain transcriptome, lipid composition and metabolism, 
oxidative stress, and mitochondrial dysfunction, resulting in modified microglial 
response and cognitive deficits (13, 258, 268, 269). Therefore, metabolic 
adaptations in transcriptome and lipid composition would contribute to additional 
imprints on microglia that accelerate the progression of consequences of 
neurodegeneration. To delineate microglial heterogeneity the integration of 
“omics” studies will refine therapeutic approaches and enhance translation of 
bench top to bed side applications. The pathways studied in this thesis present the 
initial findings that could become important in clinical diagnosis. Further 
characterizing the contributions of metabolic response within microglia are a 
burgeoning field and will provide insight to treat neuroinflammatory diseases. 
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